Lorcaserin × Cardiovascular event superiority (MACE+) — Evidence checklist

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionIs the selected question cardiovascular event superiority?Required	The preserved subclaim wording is “Cardiovascular event superiority”. MACE+ efficacy results are linked separately from the parent long-term weight-loss and lorcaserin context. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The final independent-claim count is not established.	Links between the selected subclaim, parent and MACE+ results	If the question actually changes, record the original question and excluded scope separately.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionAre subclaim grade D and its note separated from parent grade C and 50 points?Required	Subclaim grade D and “MACE+ was null, HR 0.97, P=0.55” are preserved. Subclaim score, status and axes keys are absent and left null. The parent weight evidence has grade C, 50 points and a safety warning. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. No subclaim-specific score, status or axes are present in the source.	Original locations of actual and absent subclaim fields and the parent verdict	If subclaim fields are actually added, separate the original version and change in a new event.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionAre parent axes, cross-checking and the grade decision current verification?Required	The parent’s surrogate endpoint, manufacturer-only evidence, noninferiority design, cross-checking and R1/I0/E+ are existing weight-verdict history. They are not a new clinical review or grade for this cardiovascular sheet. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. No current RoB2 assessment, methodology certification or evidence reassessment was performed.	Parent Korean and English text, axes, synthesis and verdict/correction history	Record subsequent evidence updates as separate events within the user’s requested scope.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionAt what material level did actual reading occur?Required	The entire designated source summary and selected unit were read for production. External abstracts, full text, FDA communications, registrations and protocols were neither read nor accessed. R01 R02 R03 R04 R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. External content is unread, with access not attempted.	Acquisition and reading scope for the stored summary and each external material	If material or reading history is supplied, record the actual reading level of the corresponding slot.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionHow are trials, regulatory reanalysis, reports and weight trials connected?Required	The original CAMELLIA trial, FDA cancer reanalysis of the same trial, the paper and communication describing the FDA review, BLOOM and the maintenance trial are distinguished. FDA reanalysis is not a separate efficacy trial. R01 R02 R03 R04 R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Unique-trial and participant totals and current independent replication are not established.	Relationships among citations, registrations, reports, trials and populations	If original lists are supplied, record links between the same family and separate reports.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionWho were the actual CAMELLIA participants?Required	The citation title concerns cardiovascular safety in patients with overweight or obesity. The original summary includes 12,000 participants but does not detail age, baseline cardiovascular risk or eligibility/exclusion criteria. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Exact age, baseline risk and eligibility criteria are unverified.	Participant age, diseases/risks, eligibility/exclusion and baseline characteristics	If original participant tables are supplied, distinguish the selected population and generalization scope.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionWhat were the actual lorcaserin formulation, amount and duration of use?Required	The original context of long-term lorcaserin (Belviq) use and a serotonin 2C receptor agonist for weight loss is preserved. Actual dose, formulation and dosing frequency are absent from the summary. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Formulation, dose, frequency and actual adherence/duration of use are unverified.	Trial formulation, actual intervention amount, frequency, administration/discontinuation and exposure records	If original intervention records are supplied, distinguish nominal and actual exposure and duration.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionWhat were the placebo and accompanying lifestyle care or medications?Required	CAMELLIA is preserved as a double-blind, placebo-controlled trial. Placebo formulation, shared lifestyle interventions and the content and balance of accompanying cardiovascular/diabetes treatment are absent from the summary. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Placebo composition, accompanying treatment and lifestyle content are unverified.	Placebo characteristics, shared care, accompanying medications and baseline changes	If original comparator and accompanying-intervention material is supplied, record actual between-group differences and shared exposure.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionWhat were the original randomization size and follow-up duration?Required	CAMELLIA allocated 12,000 participants in groups of 6,000, with median follow-up of 3.3 years. These describe the original allocation size and median follow-up. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Actual endpoint-specific analysis/follow-up denominators and individual follow-up durations are unverified.	Arm-specific allocation, observation, completion and analysis flow and individual follow-up windows	If original flow/follow-up tables are supplied, record the roles of each denominator and duration.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionWhat were the components and event definitions of the MACE+ efficacy endpoint?Required	The original summary labels MACE+ as the primary efficacy endpoint. Individual composite components, first/repeated events and confirmation criteria are absent from the summary. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. MACE+ components and adjudication criteria are unverified.	MACE+ components, event adjudication, repeated/first events and endpoint definitions	If original plans/result tables are supplied, separate the composite endpoint and each component event.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionWhat were the original MACE+ event counts, percentages and denominators?Required	The original summary records MACE+ in 707 lorcaserin participants (11.8%) versus 727 placebo participants (12.1%). Allocation counts of 6,000/6,000 are preserved separately. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Endpoint-specific analysis denominators, repeated-event handling and at-risk population details are unverified.	People with events/event counts, at-risk population and endpoint analysis denominators	If original event/flow tables are supplied, record whether each value concerns people, repeated events or an analysis denominator.
12	Partly verified	Full text not readStored summary read	N12 · Evidence conditionWhat were the MACE+ HR, interval and P value?Required	MACE+ HR 0.97 (0.87~1.07), P=0.55 is preserved. The confidence level of the MACE+ interval is not separately specified in that original summary. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The MACE+ interval confidence level, model and adjustments were not directly checked.	Estimation model, interval confidence level, adjustments and effect of interest	If original analysis methods/result tables are supplied, record the definitions of the original HR and interval.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionDoes null superiority mean zero effect or equivalence?Required	The subclaim note and parent describe the MACE+ superiority result as null. The original HR 0.97 (0.87~1.07), P=.55 is retained without a new zero-effect or equivalence verdict. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Prespecified superiority-analysis details and the clinical-importance threshold are unverified.	Prespecified superiority hypothesis, analysis plan and original uncertainty	If original plans are supplied, distinguish the superiority hypothesis from actual estimates and uncertainty.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionAre the MACE cardiovascular safety results preserved separately?Required	The original summary records the MACE safety endpoint in 364 participants (6.1%) versus 369 (6.2%), HR 0.99 (95% CI 0.85~1.14). It is a different endpoint from MACE+ efficacy superiority. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Detailed MACE components, analysis denominators and model are unverified.	MACE definitions, denominators, model and original safety estimates	If original safety methods/result tables are supplied, link MACE and MACE+ separately.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionTo which endpoint does the HR 1.40 noninferiority margin apply?Required	The original summary states that the prespecified HR 1.40 margin for MACE cardiovascular safety noninferiority was met. Original registration/plan text remains unread. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The original planned basis and analysis conditions for the prespecified margin were not directly read.	Planned basis for the noninferiority margin, applicable endpoint and analysis population	If original plans are supplied, distinguish the margin’s definition at the time and the reported results.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionAre the safety/efficacy endpoint hierarchy and testing order known?Required	The original summary explicitly labels MACE as the primary safety endpoint and MACE+ as the primary efficacy endpoint. Hierarchical testing order, alpha allocation and the hierarchy of additional endpoints are absent from the summary. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Actual hierarchy, multiplicity and testing order are unverified.	Endpoint hierarchy, testing order, multiplicity and change records	If the original SAP/registration is supplied, record the prespecified relationship between safety noninferiority and efficacy superiority.
17	Unverified	Full text not readStored summary read	N17 · Evidence conditionAre composite and individual cardiovascular events distinguished?Supplementary	The MACE and MACE+ composite names and original aggregations are preserved. Effects, denominators and CIs for individual components are absent from the summary. R01	Required direct details are absent from the stored summary and remain unverified. External material is unread. Direct values for death and individual cardiovascular events and overlap among components are unverified.	Definitions, aggregation, HRs/CIs and prespecified hierarchy of individual component events	If individual-event tables are supplied, separate direct results for the overall composite and each component.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionWhat was the actual cardiovascular analysis observation window?Required	Median follow-up of 3.3 years is preserved context for CAMELLIA overall. Actual MACE/MACE+ event-aggregation windows, follow-up after discontinuation and censoring times are absent from the summary. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Cardiovascular endpoint-specific time definitions and censoring are unverified.	Endpoint-specific start/end times, follow-up after discontinuation and censoring	If original follow-up/analysis records are supplied, distinguish median follow-up and actual event windows.
19	Unverified	Full text not readStored summary read	N19 · Evidence conditionWhat were the HR effect of interest, censoring and competing-risk treatment?Required	Original HRs are supplied, but proportional-hazards assumptions, ITT/actual-use estimands, censoring, competing risks and adjusted models are absent from the summary. R01	Required direct details are absent from the stored summary and remain unverified. External material is unread. HR models, effects of interest and competing-risk/censoring handling are unverified.	Effect of interest, statistical model, censoring/competing events and sensitivity analyses	If original methods/SAPs are supplied, record the actual estimands and assumptions for each cardiovascular HR.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionWhat is the scope of blinding and cardiovascular event adjudication?Required	The original summary describes CAMELLIA as double-blind and placebo-controlled. Event adjudication committees, data-collection routes and adjudication-blinding details are absent from the summary. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Role-specific blinding, independent adjudication and event-confirmation methods are unverified.	Role-specific blinding, event diagnosis/adjudication and unblinding/detection differences	If original adjudication/methods material is supplied, record actual roles and event-collection scope.
21	Unverified	Full text not readStored summary read	N21 · Evidence conditionWhat are the details of randomization, concealment and baseline balance?Required	The original scale of 12,000 participants randomized 6,000/6,000 is preserved. Sequence generation, concealment, stratification and baseline-balance details are absent from the summary. R01	Required direct details are absent from the stored summary and remain unverified. External material is unread. Allocation processes, concealment and baseline balance are unverified.	Allocation process, concealment, stratification and baseline-characteristic tables	If original allocation/baseline material is supplied, distinguish the design description from actual processes.
22	Unverified	Full text not readStored summary read	N22 · Evidence conditionHow were CAMELLIA attrition, missing data and treatment crossover handled?Required	CAMELLIA allocation size and median follow-up are available, but arm-specific attrition, treatment discontinuation, crossover, missing data and analysis-population details are absent from the summary. R01	Required direct details are absent from the stored summary and remain unverified. External material is unread. CAMELLIA endpoint-specific missing-data/attrition and ITT/PP handling details are unverified.	Arm-specific flow, discontinuation/crossover, missing-data reasons, ITT/PP and sensitivity analyses	If original flow/analysis material is supplied, distinguish allocation, use, measurement and analysis denominators.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionAre people, composite events and repeated measurements different units?Required	Original MACE/MACE+ descriptions use people and percentages; cancer diagnoses, primary-cancer counts and weight responses use other outcome units. Events and time points from the same participants are not counted as new participants. R01 R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Event overlap, repeated-event handling and exact endpoint-specific at-risk populations are unverified.	Aggregation rules for people/events/first/repeated events, time points and overlapping outcomes	If original aggregation tables are supplied, record each unit and reporting relationship.
24	Partly verified	Full text not readStored summary read	N24 · Evidence conditionWere the NCT and prespecified plans actually compared?Required	The original CAMELLIA trial and FDA reanalysis share NCT02019264. The registration identifier is preserved, but registration, protocol and SAP originals remain unread. R01 R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Direct content and timing of preregistration/plans are unverified.	Preregistration timing, endpoints/hierarchy, plan changes and analysis documents	If original registration/plan material is supplied, link actual timing and prespecified definitions.
25	Unverified	Full text not readStored summary read	N25 · Evidence conditionAre subgroup- and duration-specific cardiovascular effects known?Supplementary	The original summary contains overall MACE/MACE+ values. It lacks effect-modification results by risk, sex, comorbidities, actual exposure amount or duration. R01	Required direct details are absent from the stored summary and remain unverified. External material is unread. Direct subgroup/duration-specific estimates and interactions are unverified.	Prespecified subgroup hypotheses, interactions and arm-specific denominators/HRs/intervals	If subgroup analyses are supplied, separate overall comparisons and subgroup interactions.
26	Partly verified	Full text not readStored summary read	N26 · Evidence conditionAre superiority’s clinical importance and interpretation of all outcomes the same?Required	The original MACE+ interval and P=.55 are preserved. The superiority result is not extended to guaranteed cardiovascular-event improvement, equivalence or a single conclusion about all benefits/risks. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Prespecified MACE+ clinical-importance criteria and direct absolute effects/intervals are unverified.	Prespecified efficacy-importance criteria, absolute outcomes and individual components/quality of life	If original importance/outcome material is supplied, record statistical estimates and criteria for clinical scope separately.
27	Partly verified	Full text not readStored summary read	N27 · Evidence conditionIs the CAMELLIA one-year weight response an event effect?Supplementary	CAMELLIA at least 5% weight loss at one year was 38.7% versus 17.4%, P<0.001. The sibling response sheet preserves this response, a different question from the selected cardiovascular event superiority. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Actual endpoint-specific analysis denominators and intervals for weight response are unverified.	Boundaries between weight-response definitions, denominators/time points and direct event results	If original results are added, record weight and direct cardiovascular outcomes separately.
28	Partly verified	Full text not readStored summary read	N28 · Evidence conditionAre BLOOM weight response and retention separate context?Supplementary	BLOOM randomized 3,182 participants; at least 5% loss at 52 weeks was 47.5% versus 20.3%, with one-year retention of 55.4% (883/1595) versus 45.1% (716/1587). This is original weight context. R03	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The original BLOOM registration field is not applicable; actual registration information and cardiovascular superiority material are unverified.	BLOOM actual analysis denominators, missing data/retention and registration information	If original BLOOM material is supplied, link weight results and denominators/retention only to that trial.
29	Partly verified	Full text not readStored summary read	N29 · Evidence conditionWhat were the maintenance trial’s 24-week and 52-week results?Supplementary	The maintenance trial concerns 137 participants who lost at least 5% with a low-calorie diet. At 24 weeks, at least 5% maintenance was 73.9% versus 57.4% (P=.033), with additional −2.4±0.8 kg versus +0.6±0.8 kg (P=.010); neither 52-week co-primary result showed a between-group difference. R04	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Quantitative 52-week effects/intervals, each analysis denominator, the meaning of ± and actual registration information are unverified.	Time-specific/co-primary outcome denominators, definitions, intervals, meaning of ± and registration/analysis plans	If original maintenance material is supplied, record time points, co-primary endpoints, denominators and uncertainty.
30	Partly verified	Full text not readStored summary read	N30 · Evidence conditionWhat is the extension scope from weight/maintenance to long-term clinical events?Supplementary	The parent describes weight as a surrogate for clinical events and maintenance results as inconsistent. Cardiovascular superiority is a separate direct MACE+ result. R01 R03 R04	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Long-term clinical benefit and effects after discontinuation that cannot be explained by weight results are unverified.	Actual duration-specific clinical outcomes, weight maintenance and follow-up after discontinuation	If direct long-term results are supplied, separate trials/time points and surrogates/clinical events.
31	Partly verified	Full text not readStored summary read	N31 · Evidence conditionWhat is the original history of the developer program and independent replication?Required	The original summary states that BLOOM and CAMELLIA share a developer program with overlapping funding and authors, are not independent replication by different research teams/funders, and retain R1. R01 R03	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Current unique-trial counts and exhaustive lists of independent families are not established.	Original lists of report/developer/author/funding relationships and independent material	If relevant material is supplied, distinguish clinical-trial families from funding/author independence.
32	Partly verified	Full text not readStored summary read	N32 · Harm and regulatory scopeIn which material context do the original FDA cancer-reanalysis results belong?Supplementary	The original summary’s FDA reanalysis of completed data describes 462 people diagnosed with cancer (7.7%, 520 primary cancers) versus 423 (7.1%, 470 cancers), with pancreatic, colorectal and lung cancer imbalances contributing. It concerns safety in the same CAMELLIA trial. R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Original regulatory material and cancer-collection/adjudication details remain unread.	Original FDA communications/review material, cancer definitions, collection/adjudication and event-specific results	If original regulatory material is supplied, record the decision at the time, clinical aggregation and direct content separately.
33	Partly verified	Full text not readStored summary read	N33 · Harm and regulatory scopeAre people diagnosed with cancer and primary-cancer counts distinguished?Supplementary	Cancer diagnoses involved 462 versus 423 people, while primary-cancer counts were 520 versus 470: different units. The context is the same 12,000-participant CAMELLIA trial. R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Multiple-primary-cancer handling, follow-up/analysis denominators and cancer-type-specific values are unverified.	People/primary cancers/overlap/duration and at-risk population denominators	If original cancer-aggregation tables are supplied, link units and observation periods for people and multiple primary cancers.
34	Partly verified	Full text not readStored summary read	N34 · Harm and regulatory scopeIs one additional cancer per 470 patient-years the original estimate?Supplementary	The original FDA summary of approximately one additional cancer per 470 patient-years of treatment and a widening difference over time is preserved. R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Original estimation methods, time-specific tables and cumulative-exposure denominators are unverified.	Patient-year estimation method, observation windows and time-specific cancer/exposure denominators	If original time/analysis material is supplied, record the estimate’s observation scope and denominator.
35	Partly verified	Full text not readStored summary read	N35 · Harm and regulatory scopeAre regulatory cancer decisions and statistical confirmation distinguished?Supplementary	The original summary explicitly states that the public FDA safety communication lacked overall-cancer HR, CI and P values, and distinguishes regulatory judgment from statistically confirmed overall-cancer harm. R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Direct material on overall-cancer HR, CI, P values and prespecified clinical thresholds remains unread.	Original overall-cancer estimates/intervals, basis for regulatory decisions and prespecified thresholds	If original statistical/regulatory material is supplied, record original decisions, estimates and uncertainty separately.
36	Partly verified	Full text not readStored summary read	N36 · Harm and regulatory scopeWhat are the original date and scope of the market-withdrawal record?Supplementary	The original summary records the FDA request for voluntary withdrawal on February 13, 2020 and Eisai’s US market withdrawal in 2020. “No longer marketed” is also original wording from the existing reference date. R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Current marketing/authorization status was not externally looked up in this production.	Original FDA communication, withdrawal date/region and separate update scope for current product status	If actual status material is supplied, record withdrawal at the time and verification of current status as separate events.
37	Partly verified	Full text not readStored summary read	N37 · Harm and regulatory scopeDoes cardiovascular noninferiority substitute for cancer or overall safety?Supplementary	The original counterview explicitly states that cardiovascular noninferiority does not substitute for cancer safety. The parent safety warning is preserved as original history. R01 R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Details of all harms and other safety endpoints are unverified.	Endpoint-specific safety results, harm collection and scope of decisions	If harm material is supplied, record cardiovascular safety, cancer signals and other harms as separate endpoints.
38	Unverified	Full text not readStored summary read	N38 · Harm and regulatory scopeAre harm collection, discontinuation and missing follow-up verified?Supplementary	Cancer reanalysis and a safety warning appear in the original summary, but there are no arm-specific tables of systematic/spontaneous harm collection, severity or discontinuation/attrition. R01 R05	Required direct details are absent from the stored summary and remain unverified. External material is unread. Harm-collection methods, discontinuation/missing data and disclosure scope for all events are unverified.	All-harm collection, event definitions, discontinuation, attrition/missing data and follow-up	If original safety flow/tables are supplied, distinguish event collection, unreported results and unread material.
39	Unverified	Full text not readStored summary read	N39 · Harm and regulatory scopeWhat are alternative harm causes and long-term/rare harms or vulnerable populations?Supplementary	The original summary includes cancer imbalance over time, but lacks direct analyses of baseline cancer risk, concurrent treatment and particular populations or rare harms. R05	Required direct details are absent from the stored summary and remain unverified. External material is unread. Direct material on alternative causes, subgroups, rare harms and other long-term harms is unverified.	Baseline/concurrent risks, exposure/follow-up, population-specific harms and alternative explanations	If original long-term/population-specific material is supplied, distinguish original observations from gaps for other populations and rare harms.
40	Partly verified	Full text not readStored summary read	N40 · Harm and regulatory scopeAre harm records from regulatory reanalysis, a paper and a communication independent replication?Supplementary	The original trial and FDA reanalysis concern the same CAMELLIA population; the related review paper and communication also refer to that trial. They are not added as new independent harm trials. R01 R02 R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Independent harm replication and aggregation of new unique events are not established.	Aggregation relationships among original material/re-citations, reviews, communications and papers	If relevant original documents are supplied, record identity and event relationships between reanalysis and independent material.
41	Partly verified	Full text not readStored summary read	N41 · Evidence conditionAt what level are each report’s funding, author and operational roles recorded?Required	CAMELLIA was fully funded by Eisai, with sponsor co-design/manuscript participation and company-affiliated authors. BLOOM is described as sharing a developer program and overlapping funding/authors. The maintenance-trial funding value is “reported in the original text”. R01 R03 R04	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The maintenance trial’s specific sponsor and complete COI/data access for each report are unverified.	Original report-specific funding, product provision, analysis/reporting, author affiliations and COI disclosures	If original disclosures are supplied, record funding and operational/author roles for each report.
42	Partly verified	Full text not readStored summary read	N42 · Evidence conditionHow much of the FDA review paper was actually read?Required	A citation exists for Sharretts et al., PMID 32905671, and its original flag is “no abstract; do not guess content”. The external paper was not read in this production. R02	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The paper’s own content, direct results and disclosures remain unread.	Paper full text, citation/review context and original conflict-of-interest disclosures	If the user supplies the original full text, record material actually read separately from the FDA communication/summary.
43	Partly verified	Full text not readStored summary read	N43 · Evidence conditionIs extension to other weight-loss drugs or the class avoided?Supplementary	The original advertising discussion explains distinct withdrawal reasons: fenfluramine valvulopathy, sibutramine cardiovascular harms and rimonabant psychiatric harms. These are not direct lorcaserin cardiovascular-superiority material. R01	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Direct event effects and comparative harms of other products/classes are outside this material’s scope.	Direct product/mechanism/harm-specific material and comparison scope	If material for a separate question is supplied, write each product’s original context separately.
44	Partly verified	Full text not readStored summary read	N44 · Evidence conditionAre the reference date, corrections, Korean/English text and empty-value history preserved?Required	The reference date 2026-08-26, empty corrections array, empty deliberation string, Korean/English text and null/false/empty-string parent-axis values are preserved. Historical marketing/verdict wording is not new current verification. R01 R02 R03 R04 R05	Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Separate evidence-cutoff/facets keys are absent, and no external latest correction, withdrawal or authorization-status lookup was performed.	Original dates, corrections, current update scope and original empty values	If actual update material is supplied, distinguish the original version and a new correction event.

No items match your search or filter.

44 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Patients with overweight/obesity in the CAMELLIA citation context; exact age, baseline risk and eligibility criteria unverified
Ingredient, formulation and route: Original long-term lorcaserin (Belviq) trial intervention
Dose: Actual formulation, dose and frequency absent from the original summary and unverified; not medication/usage instructions
Comparator: Double-blind placebo control; placebo composition and shared care/accompanying treatment unverified
Measured outcome: Cardiovascular efficacy MACE+ superiority; MACE safety noninferiority, weight and cancer harms are separate context
Duration: CAMELLIA median follow-up 3.3 years; endpoint-specific event windows and individual follow-up durations unverified
Questions outside this scope: Establishing cardiovascular superiority from weight response; Using MACE noninferiority to resolve MACE+ superiority, cancer or all harms; Converting nonsignificance to zero effect or equivalence; Efficacy or safety of other drugs or the class; Verification of current marketing/authorization status, permission to take the drug or treatment instructions

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018;379:1107-1117. PMID: 30145941.

PubMed

Material type: Original CAMELLIA cardiovascular/weight trial report
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: MACE+: 707 participants (11.8%) versus 727 (12.1%), HR 0.97 (0.87~1.07), P=.55; separate MACE: 364 participants (6.1%) versus 369 (6.2%), HR 0.99 (95% CI 0.85~1.14), with original wording that the HR 1.40 noninferiority margin was met. One-year weight response is separate context.
Record level: Not recorded
Study overlap and independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Local preserved copy	Local preserved summary acquired	Summary read	The corresponding evidence-list/citation entry and parent original summary were linked for production. External originals remain unread.
External abstract	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	External abstract slot preserving the original source link; no current access, reading or link verification was performed.
External full text	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	The original source link connects identity/material and does not mean direct full-text acquisition or current content reading.
External registration	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Only the original NCT02019264 string is preserved; registration content, timing and prespecified definitions remain unread.
Required material: protocol/review methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Required scope: MACE/MACE+ definitions, testing hierarchy, models, denominators/follow-up, harms and funding roles; existence, availability and acquisition of original material are unverified.
Required material: SAP and analysis methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread.
Required material: outcomes, denominators, and harms	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Details of this material’s MACE/MACE+ definitions, testing hierarchy, models, denominators/follow-up, harms and funding roles are needed. Results or denominators from other reports are not copied.
Required materials: funding and COI	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures.

R02 · Sharretts J, Galescu O, Gomatam S, et al. Cancer Risk Associated with Lorcaserin—The FDA's Review of the CAMELLIA-TIMI 61 Trial. N Engl J Med. 2020;383:1000-1002. PMID: 32905671.

PubMed

Material type: Citation for a paper describing the FDA CAMELLIA review
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: The preserved citation records that a paper summarizing the FDA CAMELLIA review exists. Its original “no abstract; do not guess content” flag is retained. Direct paper results remain unread; FDA communication values are not attributed as directly read paper content.
Record level: Not recorded
Study overlap and independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Local preserved copy	Local preserved summary acquired	Summary read	Only citation entry 1 and the existence of the related citation in the stored summary were read. The no-abstract/do-not-guess labels were retained and direct paper content was not created.
External abstract	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	The original flag is no abstract. This is an existing record; no current access occurred and paper content was not guessed.
External full text	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	The original source link connects identity/material and does not mean direct full-text acquisition or current content reading.
External registration	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	This citation has no direct registration field; its mention of the same trial in the title is not used to fill a report-specific NCT field.
Required material: protocol/review methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Required scope: paper full text, original disclosures, actual review content and relationships with the communication/summary; existence, availability and acquisition of original material are unverified.
Required material: SAP and analysis methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread.
Required material: outcomes, denominators, and harms	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Details of this material’s paper full text, original disclosures, actual review content and relationships with the communication/summary are needed. Results or denominators from other reports are not copied.
Required materials: funding and COI	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures.

R03 · Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010. PMID: 20647200.

PubMed

Material type: BLOOM weight-loss trial report
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: 3,182 randomized participants; at least 5% loss at 52 weeks: 47.5% versus 20.3%; one-year retention: 55.4% (883/1595) versus 45.1% (716/1587). These are not repurposed as direct results for selected cardiovascular superiority.
Record level: Not recorded
Study overlap and independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Local preserved copy	Local preserved summary acquired	Summary read	The corresponding evidence-list/citation entry and parent original summary were linked for production. External originals remain unread.
External abstract	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	External abstract slot preserving the original source link; no current access, reading or link verification was performed.
External full text	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	The original source link connects identity/material and does not mean direct full-text acquisition or current content reading.
External registration	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	The original registration-identifier value “not applicable” is preserved unchanged; actual registration information and content are unverified.
Required material: protocol/review methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Required scope: weight-analysis/retention denominators, missing data, registration and funding/author relationships; existence, availability and acquisition of original material are unverified.
Required material: SAP and analysis methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread.
Required material: outcomes, denominators, and harms	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Details of this material’s weight-analysis/retention denominators, missing data, registration and funding/author relationships are needed. Results or denominators from other reports are not copied.
Required materials: funding and COI	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures.

R04 · Wadden TA, Walsh OA, Berkowitz RI, et al. A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss…. PMID: 29288545.

PubMed

Material type: Weight-loss maintenance trial report
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: Maintenance trial of 137 participants who lost at least 5% with a low-calorie diet; at 24 weeks: 73.9% versus 57.4% (P=.033), −2.4±0.8 kg versus +0.6±0.8 kg (P=.010); neither 52-week co-primary result showed a between-group difference. Not direct cardiovascular-event results.
Record level: Not recorded
Study overlap and independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Local preserved copy	Local preserved summary acquired	Summary read	The corresponding evidence-list/citation entry and parent original summary were linked for production. External originals remain unread.
External abstract	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	External abstract slot preserving the original source link; no current access, reading or link verification was performed.
External full text	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	The original source link connects identity/material and does not mean direct full-text acquisition or current content reading.
External registration	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	The original registration-identifier value “not applicable” is preserved unchanged; actual registration information and content are unverified.
Required material: protocol/review methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Required scope: time-specific co-primary outcomes/denominators, meaning of ±, 52-week intervals, plans and registration/funding; existence, availability and acquisition of original material are unverified.
Required material: SAP and analysis methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread.
Required material: outcomes, denominators, and harms	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Details of this material’s time-specific co-primary outcomes/denominators, meaning of ±, 52-week intervals, plans and registration/funding are needed. Results or denominators from other reports are not copied.
Required materials: funding and COI	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures.

R05 · US Food and Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. February 13, 2020.

Official source

Material type: FDA safety communication and regulatory-reanalysis context for the same CAMELLIA trial
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: Cancer reanalysis of the same CAMELLIA trial: 462 people diagnosed with cancer (7.7%, 520 primary cancers) versus 423 (7.1%, 470 cancers); approximately one additional cancer per 470 patient-years, with a widening difference over time. The 2020-02-13 FDA request and Eisai US withdrawal are original history; no current communication/marketing lookup was performed.
Record level: Not recorded
Study overlap and independent replication: The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Local preserved copy	Local preserved summary acquired	Summary read	The corresponding evidence-list/citation entry and parent original summary were linked for production. External originals remain unread.
External communication content	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	External FDA communication summary/content slot. It is not a PubMed paper abstract, and no current access or reading occurred.
External original communication	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	The original source link connects identity/material and does not mean direct full-text acquisition or current content reading.
External registration	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Only the original NCT02019264 string is preserved; registration content, timing and prespecified definitions remain unread.
Required material: protocol/review methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Required scope: original communication/regulatory text, cancer definitions/collection, people/cancer/time denominators and original judgments/uncertainty; existence, availability and acquisition of original material are unverified.
Required material: SAP and analysis methods	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Actual analysis material for the report, including endpoint hierarchy, models, aggregation/censoring and missing data, is needed and currently unread.
Required material: outcomes, denominators, and harms	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Details of this material’s original communication/regulatory text, cancer definitions/collection, people/cancer/time denominators and original judgments/uncertainty are needed. Results or denominators from other reports are not copied.
Required materials: funding and COI	Current public availability and detailed existence remain unverified	Access not attempted; not obtained	Not read	Original disclosures and funding/author/review roles were not directly read. Original summary funding/affiliation history is distinguished from current reading of disclosures.

Report counts versus independent study counts

The original CAMELLIA trial and FDA safety reanalysis/related paper and communication concern the same population. R02 connects only the title/citation, retaining no abstract/do not guess content; it is not added as a separate efficacy or harm replication. BLOOM is original weight-trial context sharing a developer program, funding and authors with CAMELLIA, without new independent-replication certification. The selected maintenance trial after a low-calorie diet supplies time-specific/co-primary context, not CAMELLIA cardiovascular populations/results.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Is the selected question cardiovascular event superiority?

Required materials and conditions: Links between the selected subclaim, parent and MACE+ results
Conditions for verification: Preserve exact existing wording and question/verdict records separately.
Requirement and applicability: Required
Application exceptions: Do not create new questions, hypothetical main questions or splits.
Why this condition is needed: A condition for separately recording original information and gaps for: Is the selected question cardiovascular event superiority?
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are our own design / M03 §3.2.4; our own extension boundary

N02 · Are subclaim grade D and its note separated from parent grade C and 50 points?

Required materials and conditions: Original locations of actual and absent subclaim fields and the parent verdict
Conditions for verification: Retain the distinct verdict scope of selected subclaim values and the parent.
Requirement and applicability: Required
Application exceptions: Do not fill subclaim-specific values with parent C50/E+/S/I0.
Why this condition is needed: A condition for separately recording original information and gaps for: Are subclaim grade D and its note separated from parent grade C and 50 points?
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are our own design / M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design

N03 · Are parent axes, cross-checking and the grade decision current verification?

Required materials and conditions: Parent Korean and English text, axes, synthesis and verdict/correction history
Conditions for verification: Preserve original verdict history while leaving current review of the existing content incomplete.
Requirement and applicability: Required
Application exceptions: Do not repurpose parent endpoint S or the false large hard-endpoint RCT flag as new classification or review of the selected cardiovascular endpoint.
Why this condition is needed: A condition for separately recording original information and gaps for: Are parent axes, cross-checking and the grade decision current verification?
Referenced methods: M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design / M08 §8.1–8.2.3; our own application

N04 · At what material level did actual reading occur?

Required materials and conditions: Acquisition and reading scope for the stored summary and each external material
Conditions for verification: Mark local material as summary read and external material as unread.
Requirement and applicability: Required
Application exceptions: Do not convert a URL’s presence to full-text acquisition, link verification or access failure.
Why this condition is needed: A condition for separately recording original information and gaps for: At what material level did actual reading occur?
Referenced methods: M04 §4.5–4.6 material-collection and selection principles; separation of access and reading and hyperlink rules are our own design / M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design

N05 · How are trials, regulatory reanalysis, reports and weight trials connected?

Required materials and conditions: Relationships among citations, registrations, reports, trials and populations
Conditions for verification: Distinguish report-entry counts from unestablished unique-trial and population counts.
Requirement and applicability: Required
Application exceptions: Do not add people, cancer events or regulatory documents from the same CAMELLIA trial as new trials or participants.
Why this condition is needed: A condition for separately recording original information and gaps for: How are trials, regulatory reanalysis, reports and weight trials connected?
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort and outcome linking is our own application / M04 §4.6.1–4.6.2, M15 §15.3.1; our own application

N06 · Who were the actual CAMELLIA participants?

Required materials and conditions: Participant age, diseases/risks, eligibility/exclusion and baseline characteristics
Conditions for verification: Retain the original participant wording and gaps in detailed selection conditions.
Requirement and applicability: Required
Application exceptions: Do not certify event effects for all adults or all patients with obesity from a citation title alone.
Why this condition is needed: A condition for separately recording original information and gaps for: Who were the actual CAMELLIA participants?
Referenced methods: M03 §3.2.1; detailed population conditions are our own design / M03 §3.2.1–3.2.4; dose, persistence and effect-modification details are our own design

N07 · What were the actual lorcaserin formulation, amount and duration of use?

Required materials and conditions: Trial formulation, actual intervention amount, frequency, administration/discontinuation and exposure records
Conditions for verification: Separate the original intervention name from gaps in actual exposure details.
Requirement and applicability: Required
Application exceptions: Do not create medication instructions or doses absent from the source.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the actual lorcaserin formulation, amount and duration of use?
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and assessment adaptations are our own design / M03 §3.2.3, M08 §8.2.2–8.2.3; our own application

N08 · What were the placebo and accompanying lifestyle care or medications?

Required materials and conditions: Placebo characteristics, shared care, accompanying medications and baseline changes
Conditions for verification: Separate the original comparator type from unverified specific comparison conditions.
Requirement and applicability: Required
Application exceptions: Do not convert placebo control to a no-care or no-treatment comparison.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the placebo and accompanying lifestyle care or medications?
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and assessment adaptations are our own design / M03 §3.2.3, M08 §8.2.2–8.2.3; our own application / M19 §19.2.2–19.2.4 design considerations; detailed confounding records are our own design

N09 · What were the original randomization size and follow-up duration?

Required materials and conditions: Arm-specific allocation, observation, completion and analysis flow and individual follow-up windows
Conditions for verification: Record allocation denominators and median follow-up separately from actual endpoint-specific denominators.
Requirement and applicability: Required
Application exceptions: Do not make median 3.3-year follow-up the same follow-up time for every participant.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the original randomization size and follow-up duration?
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M08 §8.1–8.2.3; Chamgap adaptation / M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design

N10 · What were the components and event definitions of the MACE+ efficacy endpoint?

Required materials and conditions: MACE+ components, event adjudication, repeated/first events and endpoint definitions
Conditions for verification: Preserve the original MACE+ name and leave specific components unverified.
Requirement and applicability: Required
Application exceptions: Do not fill in guessed conventional MACE definitions or components from other material.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the components and event definitions of the MACE+ efficacy endpoint?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design / M08 Table 8.2.a, M03 §3.2.4; our own application

N11 · What were the original MACE+ event counts, percentages and denominators?

Required materials and conditions: People with events/event counts, at-risk population and endpoint analysis denominators
Conditions for verification: Retain original people/percentages and allocation denominators unchanged.
Requirement and applicability: Required
Application exceptions: Do not recalculate original percentages or add the two arms or events together.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the original MACE+ event counts, percentages and denominators?
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design

N12 · What were the MACE+ HR, interval and P value?

Required materials and conditions: Estimation model, interval confidence level, adjustments and effect of interest
Conditions for verification: Preserve original MACE+ HR, interval and P value at each originally stated level.
Requirement and applicability: Required
Application exceptions: Do not automatically copy the explicit MACE 95% level to the MACE+ interval or calculate new HRs/CIs.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the MACE+ HR, interval and P value?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design / M15 §15.3.1–15.3.3; our own application

N13 · Does null superiority mean zero effect or equivalence?

Required materials and conditions: Prespecified superiority hypothesis, analysis plan and original uncertainty
Conditions for verification: Preserve the original null-result description together with the uncertainty interval.
Requirement and applicability: Required
Application exceptions: Do not convert nonsignificance to zero event difference, equivalence or a personal safety guarantee.
Why this condition is needed: A condition for separately recording original information and gaps for: Does null superiority mean zero effect or equivalence?
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design / M15 §15.3.1–15.3.3; Chamgap adaptation

N14 · Are the MACE cardiovascular safety results preserved separately?

Required materials and conditions: MACE definitions, denominators, model and original safety estimates
Conditions for verification: Keep original MACE safety values separate from MACE+ efficacy values.
Requirement and applicability: Required
Application exceptions: Do not repurpose MACE numbers/CIs as MACE+ efficacy results.
Why this condition is needed: A condition for separately recording original information and gaps for: Are the MACE cardiovascular safety results preserved separately?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is our own design

N15 · To which endpoint does the HR 1.40 noninferiority margin apply?

Required materials and conditions: Planned basis for the noninferiority margin, applicable endpoint and analysis population
Conditions for verification: Link the original margin, applicable MACE endpoint and unread external plans.
Requirement and applicability: Required
Application exceptions: Do not use HR 1.40 as a threshold for MACE+ superiority, cancer safety or overall harmlessness.
Why this condition is needed: A condition for separately recording original information and gaps for: To which endpoint does the HR 1.40 noninferiority margin apply?
Referenced methods: M15 §15.3.1–15.3.3; Chamgap adaptation / M08 Table 8.2.a, M04 §4.6.3; Chamgap adaptation

N16 · Are the safety/efficacy endpoint hierarchy and testing order known?

Required materials and conditions: Endpoint hierarchy, testing order, multiplicity and change records
Conditions for verification: Distinguish original endpoint roles and unverified hierarchy details.
Requirement and applicability: Required
Application exceptions: Do not promote the two primary-endpoint labels to direct certification of all testing procedures.
Why this condition is needed: A condition for separately recording original information and gaps for: Are the safety/efficacy endpoint hierarchy and testing order known?
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap adaptation / M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design

N17 · Are composite and individual cardiovascular events distinguished?

Required materials and conditions: Definitions, aggregation, HRs/CIs and prespecified hierarchy of individual component events
Conditions for verification: Retain the boundary between composite endpoints and unverified individual clinical outcomes.
Requirement and applicability: Supplementary
Application exceptions: Do not copy a composite HR as every individual-event HR or mortality benefit.
Why this condition is needed: A condition for separately recording original information and gaps for: Are composite and individual cardiovascular events distinguished?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design / M03 §3.2.4; our own extension boundary

N18 · What was the actual cardiovascular analysis observation window?

Required materials and conditions: Endpoint-specific start/end times, follow-up after discontinuation and censoring
Conditions for verification: Separate original duration descriptions from endpoint-specific timing gaps.
Requirement and applicability: Required
Application exceptions: Do not replace all event windows with the one-year weight time point or median 3.3 years.
Why this condition is needed: A condition for separately recording original information and gaps for: What was the actual cardiovascular analysis observation window?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design

N19 · What were the HR effect of interest, censoring and competing-risk treatment?

Required materials and conditions: Effect of interest, statistical model, censoring/competing events and sensitivity analyses
Conditions for verification: Separate original HRs from unverified analysis assumptions.
Requirement and applicability: Required
Application exceptions: Do not interpret an HR as a simple risk ratio or individual prevention probability, or convert it to new values.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the HR effect of interest, censoring and competing-risk treatment?
Referenced methods: M08 §8.2.2, M15 §15.3.1; our own application / M15 §15.3.1–15.3.3; our own application / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design

N20 · What is the scope of blinding and cardiovascular event adjudication?

Required materials and conditions: Role-specific blinding, event diagnosis/adjudication and unblinding/detection differences
Conditions for verification: Separate the original design label from gaps in adjudication details.
Requirement and applicability: Required
Application exceptions: Do not extend a double-blind label to certification of every outcome-adjudication or analysis process.
Why this condition is needed: A condition for separately recording original information and gaps for: What is the scope of blinding and cardiovascular event adjudication?
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; our own application / M08 §8.1–8.2.3; our own application

N21 · What are the details of randomization, concealment and baseline balance?

Required materials and conditions: Allocation process, concealment, stratification and baseline-characteristic tables
Conditions for verification: Keep original allocation labels separate from gaps in direct methods.
Requirement and applicability: Required
Application exceptions: Do not declare all bias conditions satisfied from a randomized label alone.
Why this condition is needed: A condition for separately recording original information and gaps for: What are the details of randomization, concealment and baseline balance?
Referenced methods: M08 §8.1–8.2.3; our own application / M03 §3.2.1; detailed population conditions are our own design

N22 · How were CAMELLIA attrition, missing data and treatment crossover handled?

Required materials and conditions: Arm-specific flow, discontinuation/crossover, missing-data reasons, ITT/PP and sensitivity analyses
Conditions for verification: Do not mix denominators and missing-data material across trials.
Requirement and applicability: Required
Application exceptions: Do not transfer BLOOM retention as CAMELLIA follow-up/analysis percentages.
Why this condition is needed: A condition for separately recording original information and gaps for: How were CAMELLIA attrition, missing data and treatment crossover handled?
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design / M08 §8.2.2, M15 §15.3.1; our own application / M19 §19.1.2–19.2.4, M04 §4.6.3; our own application

N23 · Are people, composite events and repeated measurements different units?

Required materials and conditions: Aggregation rules for people/events/first/repeated events, time points and overlapping outcomes
Conditions for verification: Retain original units and do not create unestablished totals.
Requirement and applicability: Required
Application exceptions: Do not add counts from different endpoints/time points as independent populations or total events.
Why this condition is needed: A condition for separately recording original information and gaps for: Are people, composite events and repeated measurements different units?
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation

N24 · Were the NCT and prespecified plans actually compared?

Required materials and conditions: Preregistration timing, endpoints/hierarchy, plan changes and analysis documents
Conditions for verification: Distinguish original registration strings and the scope of unread external material.
Requirement and applicability: Required
Application exceptions: Do not count the same NCT as two independent-trial registrations or convert it to certification of prespecification.
Why this condition is needed: A condition for separately recording original information and gaps for: Were the NCT and prespecified plans actually compared?
Referenced methods: M04 §4.5–4.6 provide collection and selection principles; separating access from reading and the hyperlink convention are our own design / M08 Table 8.2.a, M04 §4.6.3; our own application

N25 · Are subgroup- and duration-specific cardiovascular effects known?

Required materials and conditions: Prespecified subgroup hypotheses, interactions and arm-specific denominators/HRs/intervals
Conditions for verification: Retain gaps in direct evidence outside the overall results.
Requirement and applicability: Supplementary
Application exceptions: Do not copy the overall HR as an effect for specific populations, durations or optimal exposure.
Why this condition is needed: A condition for separately recording original information and gaps for: Are subgroup- and duration-specific cardiovascular effects known?
Referenced methods: M03 §3.2.1; detailed population conditions are our own design / M03 §3.2.1–3.2.4; dose, persistence and effect-modification details are our own design

N26 · Are superiority’s clinical importance and interpretation of all outcomes the same?

Required materials and conditions: Prespecified efficacy-importance criteria, absolute outcomes and individual components/quality of life
Conditions for verification: Retain the original superiority result’s scope without thresholds from other endpoints.
Requirement and applicability: Required
Application exceptions: Do not use the MACE noninferiority HR 1.40 as an efficacy-importance threshold.
Why this condition is needed: A condition for separately recording original information and gaps for: Are superiority’s clinical importance and interpretation of all outcomes the same?
Referenced methods: M15 §15.3.1–15.3.3; our own application / M03 §3.2.4; our own boundary on extensions

N27 · Is the CAMELLIA one-year weight response an event effect?

Required materials and conditions: Boundaries between weight-response definitions, denominators/time points and direct event results
Conditions for verification: Preserve sibling context without adding it as new questions or trials.
Requirement and applicability: Supplementary
Application exceptions: Do not transfer positive weight response as MACE+ superiority or a selected subclaim score.
Why this condition is needed: A condition for separately recording original information and gaps for: Is the CAMELLIA one-year weight response an event effect?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design / M03 §3.2.4; Chamgap extension boundary / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design

N28 · Are BLOOM weight response and retention separate context?

Required materials and conditions: BLOOM actual analysis denominators, missing data/retention and registration information
Conditions for verification: Retain the boundary between a separate weight trial and selected cardiovascular results.
Requirement and applicability: Supplementary
Application exceptions: Do not repurpose BLOOM weight/retention values as CAMELLIA events or attrition.
Why this condition is needed: A condition for separately recording original information and gaps for: Are BLOOM weight response and retention separate context?
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M03 §3.2.4; Chamgap extension boundary

N29 · What were the maintenance trial’s 24-week and 52-week results?

Required materials and conditions: Time-specific/co-primary outcome denominators, definitions, intervals, meaning of ± and registration/analysis plans
Conditions for verification: Preserve original maintenance results and time-specific gaps separately.
Requirement and applicability: Supplementary
Application exceptions: Do not transfer a 24-week signal as 52-week weight maintenance or CAMELLIA cardiovascular events.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the maintenance trial’s 24-week and 52-week results?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design / M08 Table 8.2.a, M04 §4.6.3; Chamgap adaptation / M03 §3.2.4; Chamgap extension boundary

N30 · What is the extension scope from weight/maintenance to long-term clinical events?

Required materials and conditions: Actual duration-specific clinical outcomes, weight maintenance and follow-up after discontinuation
Conditions for verification: Preserve the different outcomes of weight signals and direct cardiovascular events.
Requirement and applicability: Supplementary
Application exceptions: Do not automatically extend weight loss to improved long-term events, mortality or quality of life.
Why this condition is needed: A condition for separately recording original information and gaps for: What is the extension scope from weight/maintenance to long-term clinical events?
Referenced methods: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap design / M03 §3.2.4; Chamgap extension boundary

N31 · What is the original history of the developer program and independent replication?

Required materials and conditions: Original lists of report/developer/author/funding relationships and independent material
Conditions for verification: Preserve original nonindependent-program history without new independence certification.
Requirement and applicability: Required
Application exceptions: Do not calculate independent-replication counts from separate trial/citation counts or regulatory reviews.
Why this condition is needed: A condition for separately recording original information and gaps for: What is the original history of the developer program and independent replication?
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation / Chamgap’s own independence/attribution conditions. The official methodological sections in this pilot do not warrant all these detailed items / M04 §4.6.1–4.6.2, M15 §15.3.1; Chamgap adaptation

N32 · In which material context do the original FDA cancer-reanalysis results belong?

Required materials and conditions: Original FDA communications/review material, cancer definitions, collection/adjudication and event-specific results
Conditions for verification: Preserve the original FDA summary as regulatory/safety context.
Requirement and applicability: Supplementary
Application exceptions: Do not turn regulatory reanalysis into a separate efficacy trial, new participants or directly read paper results.
Why this condition is needed: A condition for separately recording original information and gaps for: In which material context do the original FDA cancer-reanalysis results belong?
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M19 §19.1.2–19.2.4; detailed discrimination is Chamgap design

N33 · Are people diagnosed with cancer and primary-cancer counts distinguished?

Required materials and conditions: People/primary cancers/overlap/duration and at-risk population denominators
Conditions for verification: Keep original people, counts and percentages separated and unchanged.
Requirement and applicability: Supplementary
Application exceptions: Do not add people with cancer and cancer counts or back-calculate duplicate people.
Why this condition is needed: A condition for separately recording original information and gaps for: Are people diagnosed with cancer and primary-cancer counts distinguished?
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation

N34 · Is one additional cancer per 470 patient-years the original estimate?

Required materials and conditions: Patient-year estimation method, observation windows and time-specific cancer/exposure denominators
Conditions for verification: Retain time/units and estimation limitations in the original regulatory summary.
Requirement and applicability: Supplementary
Application exceptions: Do not convert the original 470 patient-years value to individual risk, a new NNH or back-calculated events.
Why this condition is needed: A condition for separately recording original information and gaps for: Is one additional cancer per 470 patient-years the original estimate?
Referenced methods: M19 §19.2 design-specific harm questions; temporal-relationship details are Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M19 §19.1.2–19.2.4; Chamgap adaptation

N35 · Are regulatory cancer decisions and statistical confirmation distinguished?

Required materials and conditions: Original overall-cancer estimates/intervals, basis for regulatory decisions and prespecified thresholds
Conditions for verification: Distinguish original regulatory judgments from gaps in direct statistical material.
Requirement and applicability: Supplementary
Application exceptions: Do not calculate or invent new cancer HRs/CIs/P values, statistical significance or causal certification.
Why this condition is needed: A condition for separately recording original information and gaps for: Are regulatory cancer decisions and statistical confirmation distinguished?
Referenced methods: Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool / M19 §19.1.2–19.2.4; Chamgap adaptation / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design

N36 · What are the original date and scope of the market-withdrawal record?

Required materials and conditions: Original FDA communication, withdrawal date/region and separate update scope for current product status
Conditions for verification: Retain original dates and US withdrawal alongside the scope not currently looked up.
Requirement and applicability: Supplementary
Application exceptions: Do not promote original historical status to a completed current authorization/marketing lookup.
Why this condition is needed: A condition for separately recording original information and gaps for: What are the original date and scope of the market-withdrawal record?
Referenced methods: M04 §4.5, §4.6.3; limitations of the current material conversion follow the review scope and Chamgap design / Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool

N37 · Does cardiovascular noninferiority substitute for cancer or overall safety?

Required materials and conditions: Endpoint-specific safety results, harm collection and scope of decisions
Conditions for verification: Separate endpoint-specific safety scope and other long-term harms.
Requirement and applicability: Supplementary
Application exceptions: Do not convert meeting MACE noninferiority to absence of all harms or permission to take the drug.
Why this condition is needed: A condition for separately recording original information and gaps for: Does cardiovascular noninferiority substitute for cancer or overall safety?
Referenced methods: M19 §19.2.2–19.2.4, M03 §3.2.3; Chamgap adaptation / Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool / M19 §19.1.2–19.2.4; Chamgap adaptation

N38 · Are harm collection, discontinuation and missing follow-up verified?

Required materials and conditions: All-harm collection, event definitions, discontinuation, attrition/missing data and follow-up
Conditions for verification: Distinguish currently unread material from confirmation that original results were unreported.
Requirement and applicability: Supplementary
Application exceptions: Do not label a safety summary’s presence as complete collection of all harms or zero events.
Why this condition is needed: A condition for separately recording original information and gaps for: Are harm collection, discontinuation and missing follow-up verified?
Referenced methods: M19 §19.1.2–19.2.4; detailed discrimination is Chamgap design / M19 §19.1.2–19.2.4, M04 §4.6.3; Chamgap adaptation / M08 §8.2.2, M15 §15.3.1; Chamgap adaptation

N39 · What are alternative harm causes and long-term/rare harms or vulnerable populations?

Required materials and conditions: Baseline/concurrent risks, exposure/follow-up, population-specific harms and alternative explanations
Conditions for verification: Distinguish original signals from unverified alternatives or extension scope.
Requirement and applicability: Supplementary
Application exceptions: Do not establish a regulatory signal as causality or risk magnitude for all participants, exposures or the class.
Why this condition is needed: A condition for separately recording original information and gaps for: What are alternative harm causes and long-term/rare harms or vulnerable populations?
Referenced methods: M19 §19.2.2–19.2.4 design considerations; detailed confounding records are Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap design

N40 · Are harm records from regulatory reanalysis, a paper and a communication independent replication?

Required materials and conditions: Aggregation relationships among original material/re-citations, reviews, communications and papers
Conditions for verification: Preserve relationships between document slots and the original population.
Requirement and applicability: Supplementary
Application exceptions: Do not count three documents, the same registration and the same cancer records as three independent populations.
Why this condition is needed: A condition for separately recording original information and gaps for: Are harm records from regulatory reanalysis, a paper and a communication independent replication?
Referenced methods: M04 §4.6.1–4.6.2; harm-material adaptations are Chamgap designs / M04 §4.6.1–4.6.2 on distinguishing studies from reports; cohort and outcome connections are Chamgap adaptations

N41 · At what level are each report’s funding, author and operational roles recorded?

Required materials and conditions: Original report-specific funding, product provision, analysis/reporting, author affiliations and COI disclosures
Conditions for verification: Retain original report-specific roles/funding descriptions and gaps separately.
Requirement and applicability: Required
Application exceptions: Do not convert “reported in the original text” to full-text reading in this production or establishment of a specific sponsor.
Why this condition is needed: A condition for separately recording original information and gaps for: At what level are each report’s funding, author and operational roles recorded?
Referenced methods: CHAMGAP's own independence and attribution conditions. Official methodological sections used in this pilot do not guarantee every detail of this item / M04 §4.6.1–4.6.2, M15 §15.3.1; our own application

N42 · How much of the FDA review paper was actually read?

Required materials and conditions: Paper full text, citation/review context and original conflict-of-interest disclosures
Conditions for verification: Retain original citation/no-abstract labels and unread status.
Requirement and applicability: Required
Application exceptions: Do not claim FDA communication values were directly read in the paper because its title mentions the same trial.
Why this condition is needed: A condition for separately recording original information and gaps for: How much of the FDA review paper was actually read?
Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and the hyperlink contract are Chamgap design / M04 §4.5, §4.6.3; limitations of the current material conversion follow the review scope and Chamgap design / Chamgap’s own independence/attribution conditions. The official methodological sections in this pilot do not warrant all these detailed items

N43 · Is extension to other weight-loss drugs or the class avoided?

Required materials and conditions: Direct product/mechanism/harm-specific material and comparison scope
Conditions for verification: Retain original extension limitations and do not mix results from other products.
Requirement and applicability: Supplementary
Application exceptions: Do not apply lorcaserin results to other products or the whole class, or create new treatment-selection instructions.
Why this condition is needed: A condition for separately recording original information and gaps for: Is extension to other weight-loss drugs or the class avoided?
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap design / M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are Chamgap design / M03 §3.2.4; Chamgap extension boundary / Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool

N44 · Are the reference date, corrections, Korean/English text and empty-value history preserved?

Required materials and conditions: Original dates, corrections, current update scope and original empty values
Conditions for verification: Link original languages, dates and empty values with the actual current reading scope.
Requirement and applicability: Required
Application exceptions: Do not borrow the existing reference date as a current review date or convert an empty corrections array to certification that no corrections exist anywhere.
Why this condition is needed: A condition for separately recording original information and gaps for: Are the reference date, corrections, Korean/English text and empty-value history preserved?
Referenced methods: M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design / M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are our own design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

What the statuses mean

Met: The original content has been reviewed as meeting the conditions. This status is not used in this preparation.
Partly verified: Some information in the stored summary was linked during preparation; clinical verification or review is not complete.
Unverified: Required direct values, definitions or materials have not been established within the current storage and reading scope. This does not mean zero effect, no papers or failed access.
Review incomplete: Review of existing content or actual review incomplete.
Not reported: Used only when original materials were actually read and the outcome was judged unreported. Not used for external materials unread in this work.
Inaccessible: Used only when an actual access attempt has a recorded failure. Not used for access that was not attempted in this work.
Insufficient evidence for the conditions: Indicates insufficient direct materials for the relevant scope or conditions; it is not a new grade.
Not applicable: Used when the reason it does not apply to the original question is stated.
Conflicting data: Retains the scope of conflicting statements in original materials; it is not an arbitrary reassessment.

Change history

2026-10-11 · Public page/material version 1.0

A public view and materials were prepared from the existing 44 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Is the selected question cardiovascular event superiority?

Current findings: The preserved subclaim wording is “Cardiovascular event superiority”. MACE+ efficacy results are linked separately from the parent long-term weight-loss and lorcaserin context.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The final independent-claim count is not established.
Reason for missing information: The final count of independent claims remains undetermined.
Required materials and conditions: Links between the selected subclaim, parent and MACE+ results
Materials to obtain first: Links between the selected subclaim, parent and MACE+ results
Further research: If the question actually changes, record the original question and excluded scope separately.
Remaining uncertainty: Do not create new questions, hypothetical main questions or splits. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve exact existing wording and question/verdict records separately.
Why this condition is needed: A condition for separately recording original information and gaps for: Is the selected question cardiovascular event superiority?
Application exceptions: Do not create new questions, hypothetical main questions or splits.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are our own design / M03 §3.2.4; our own extension boundary

Related sources R01

N02 · Are subclaim grade D and its note separated from parent grade C and 50 points?

Current findings: Subclaim grade D and “MACE+ was null, HR 0.97, P=0.55” are preserved. Subclaim score, status and axes keys are absent and left null. The parent weight evidence has grade C, 50 points and a safety warning.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. No subclaim-specific score, status or axes are present in the source.
Reason for missing information: The original record has no subclaim-specific score, status or axes.
Required materials and conditions: Original locations of actual and absent subclaim fields and the parent verdict
Materials to obtain first: Original locations of actual and absent subclaim fields and the parent verdict
Further research: If subclaim fields are actually added, separate the original version and change in a new event.
Remaining uncertainty: Do not fill subclaim-specific values with parent C50/E+/S/I0. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain the distinct verdict scope of selected subclaim values and the parent.
Why this condition is needed: A condition for separately recording original information and gaps for: Are subclaim grade D and its note separated from parent grade C and 50 points?
Application exceptions: Do not fill subclaim-specific values with parent C50/E+/S/I0.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are our own design / M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design

Related sources R01

N03 · Are parent axes, cross-checking and the grade decision current verification?

Current findings: The parent’s surrogate endpoint, manufacturer-only evidence, noninferiority design, cross-checking and R1/I0/E+ are existing weight-verdict history. They are not a new clinical review or grade for this cardiovascular sheet.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. No current RoB2 assessment, methodology certification or evidence reassessment was performed.
Reason for missing information: No current RoB2 assessment, methodology certification or evidence reassessment was performed.
Required materials and conditions: Parent Korean and English text, axes, synthesis and verdict/correction history
Materials to obtain first: Parent Korean and English text, axes, synthesis and verdict/correction history
Further research: Record subsequent evidence updates as separate events within the user’s requested scope.
Remaining uncertainty: Do not repurpose parent endpoint S or the false large hard-endpoint RCT flag as new classification or review of the selected cardiovascular endpoint. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve original verdict history while leaving current review of the existing content incomplete.
Why this condition is needed: A condition for separately recording original information and gaps for: Are parent axes, cross-checking and the grade decision current verification?
Application exceptions: Do not repurpose parent endpoint S or the false large hard-endpoint RCT flag as new classification or review of the selected cardiovascular endpoint.
Referenced methods: M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design / M08 §8.1–8.2.3; our own application

Related sources R01

N04 · At what material level did actual reading occur?

Current findings: The entire designated source summary and selected unit were read for production. External abstracts, full text, FDA communications, registrations and protocols were neither read nor accessed.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. External content is unread, with access not attempted.
Reason for missing information: External content is unread, with access not attempted.
Required materials and conditions: Acquisition and reading scope for the stored summary and each external material
Materials to obtain first: Acquisition and reading scope for the stored summary and each external material
Further research: If material or reading history is supplied, record the actual reading level of the corresponding slot.
Remaining uncertainty: Do not convert a URL’s presence to full-text acquisition, link verification or access failure. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Mark local material as summary read and external material as unread.
Why this condition is needed: A condition for separately recording original information and gaps for: At what material level did actual reading occur?
Application exceptions: Do not convert a URL’s presence to full-text acquisition, link verification or access failure.
Referenced methods: M04 §4.5–4.6 material-collection and selection principles; separation of access and reading and hyperlink rules are our own design / M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design

Related sources R01 R02 R03 R04 R05

N05 · How are trials, regulatory reanalysis, reports and weight trials connected?

Current findings: The original CAMELLIA trial, FDA cancer reanalysis of the same trial, the paper and communication describing the FDA review, BLOOM and the maintenance trial are distinguished. FDA reanalysis is not a separate efficacy trial.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Unique-trial and participant totals and current independent replication are not established.
Reason for missing information: Unique-trial and participant totals and current independent replication are not established.
Required materials and conditions: Relationships among citations, registrations, reports, trials and populations
Materials to obtain first: Relationships among citations, registrations, reports, trials and populations
Further research: If original lists are supplied, record links between the same family and separate reports.
Remaining uncertainty: Do not add people, cancer events or regulatory documents from the same CAMELLIA trial as new trials or participants. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Distinguish report-entry counts from unestablished unique-trial and population counts.
Why this condition is needed: A condition for separately recording original information and gaps for: How are trials, regulatory reanalysis, reports and weight trials connected?
Application exceptions: Do not add people, cancer events or regulatory documents from the same CAMELLIA trial as new trials or participants.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort and outcome linking is our own application / M04 §4.6.1–4.6.2, M15 §15.3.1; our own application

Related sources R01 R02 R03 R04 R05

N06 · Who were the actual CAMELLIA participants?

Current findings: The citation title concerns cardiovascular safety in patients with overweight or obesity. The original summary includes 12,000 participants but does not detail age, baseline cardiovascular risk or eligibility/exclusion criteria.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Exact age, baseline risk and eligibility criteria are unverified.
Reason for missing information: Exact age, baseline risk and eligibility criteria are unverified.
Required materials and conditions: Participant age, diseases/risks, eligibility/exclusion and baseline characteristics
Materials to obtain first: Participant age, diseases/risks, eligibility/exclusion and baseline characteristics
Further research: If original participant tables are supplied, distinguish the selected population and generalization scope.
Remaining uncertainty: Do not certify event effects for all adults or all patients with obesity from a citation title alone. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain the original participant wording and gaps in detailed selection conditions.
Why this condition is needed: A condition for separately recording original information and gaps for: Who were the actual CAMELLIA participants?
Application exceptions: Do not certify event effects for all adults or all patients with obesity from a citation title alone.
Referenced methods: M03 §3.2.1; detailed population conditions are our own design / M03 §3.2.1–3.2.4; dose, persistence and effect-modification details are our own design

Related sources R01

N07 · What were the actual lorcaserin formulation, amount and duration of use?

Current findings: The original context of long-term lorcaserin (Belviq) use and a serotonin 2C receptor agonist for weight loss is preserved. Actual dose, formulation and dosing frequency are absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Formulation, dose, frequency and actual adherence/duration of use are unverified.
Reason for missing information: Formulation, dose, frequency and actual adherence/duration of use are unverified.
Required materials and conditions: Trial formulation, actual intervention amount, frequency, administration/discontinuation and exposure records
Materials to obtain first: Trial formulation, actual intervention amount, frequency, administration/discontinuation and exposure records
Further research: If original intervention records are supplied, distinguish nominal and actual exposure and duration.
Remaining uncertainty: Do not create medication instructions or doses absent from the source. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Separate the original intervention name from gaps in actual exposure details.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the actual lorcaserin formulation, amount and duration of use?
Application exceptions: Do not create medication instructions or doses absent from the source.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and assessment adaptations are our own design / M03 §3.2.3, M08 §8.2.2–8.2.3; our own application

Related sources R01

N08 · What were the placebo and accompanying lifestyle care or medications?

Current findings: CAMELLIA is preserved as a double-blind, placebo-controlled trial. Placebo formulation, shared lifestyle interventions and the content and balance of accompanying cardiovascular/diabetes treatment are absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Placebo composition, accompanying treatment and lifestyle content are unverified.
Reason for missing information: Placebo composition, accompanying treatment and lifestyle content are unverified.
Required materials and conditions: Placebo characteristics, shared care, accompanying medications and baseline changes
Materials to obtain first: Placebo characteristics, shared care, accompanying medications and baseline changes
Further research: If original comparator and accompanying-intervention material is supplied, record actual between-group differences and shared exposure.
Remaining uncertainty: Do not convert placebo control to a no-care or no-treatment comparison. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Separate the original comparator type from unverified specific comparison conditions.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the placebo and accompanying lifestyle care or medications?
Application exceptions: Do not convert placebo control to a no-care or no-treatment comparison.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and assessment adaptations are our own design / M03 §3.2.3, M08 §8.2.2–8.2.3; our own application / M19 §19.2.2–19.2.4 design considerations; detailed confounding records are our own design

Related sources R01

N09 · What were the original randomization size and follow-up duration?

Current findings: CAMELLIA allocated 12,000 participants in groups of 6,000, with median follow-up of 3.3 years. These describe the original allocation size and median follow-up.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Actual endpoint-specific analysis/follow-up denominators and individual follow-up durations are unverified.
Reason for missing information: Actual endpoint-specific analysis/follow-up denominators and individual follow-up durations are unverified.
Required materials and conditions: Arm-specific allocation, observation, completion and analysis flow and individual follow-up windows
Materials to obtain first: Arm-specific allocation, observation, completion and analysis flow and individual follow-up windows
Further research: If original flow/follow-up tables are supplied, record the roles of each denominator and duration.
Remaining uncertainty: Do not make median 3.3-year follow-up the same follow-up time for every participant. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Record allocation denominators and median follow-up separately from actual endpoint-specific denominators.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the original randomization size and follow-up duration?
Application exceptions: Do not make median 3.3-year follow-up the same follow-up time for every participant.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M08 §8.1–8.2.3; Chamgap adaptation / M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design

Related sources R01

N10 · What were the components and event definitions of the MACE+ efficacy endpoint?

Current findings: The original summary labels MACE+ as the primary efficacy endpoint. Individual composite components, first/repeated events and confirmation criteria are absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. MACE+ components and adjudication criteria are unverified.
Reason for missing information: MACE+ components and adjudication criteria are unverified.
Required materials and conditions: MACE+ components, event adjudication, repeated/first events and endpoint definitions
Materials to obtain first: MACE+ components, event adjudication, repeated/first events and endpoint definitions
Further research: If original plans/result tables are supplied, separate the composite endpoint and each component event.
Remaining uncertainty: Do not fill in guessed conventional MACE definitions or components from other material. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve the original MACE+ name and leave specific components unverified.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the components and event definitions of the MACE+ efficacy endpoint?
Application exceptions: Do not fill in guessed conventional MACE definitions or components from other material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design / M08 Table 8.2.a, M03 §3.2.4; our own application

Related sources R01

N11 · What were the original MACE+ event counts, percentages and denominators?

Current findings: The original summary records MACE+ in 707 lorcaserin participants (11.8%) versus 727 placebo participants (12.1%). Allocation counts of 6,000/6,000 are preserved separately.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Endpoint-specific analysis denominators, repeated-event handling and at-risk population details are unverified.
Reason for missing information: Endpoint-specific analysis denominators, repeated-event handling and at-risk population details are unverified.
Required materials and conditions: People with events/event counts, at-risk population and endpoint analysis denominators
Materials to obtain first: People with events/event counts, at-risk population and endpoint analysis denominators
Further research: If original event/flow tables are supplied, record whether each value concerns people, repeated events or an analysis denominator.
Remaining uncertainty: Do not recalculate original percentages or add the two arms or events together. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain original people/percentages and allocation denominators unchanged.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the original MACE+ event counts, percentages and denominators?
Application exceptions: Do not recalculate original percentages or add the two arms or events together.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design

Related sources R01

N12 · What were the MACE+ HR, interval and P value?

Current findings: MACE+ HR 0.97 (0.87~1.07), P=0.55 is preserved. The confidence level of the MACE+ interval is not separately specified in that original summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The MACE+ interval confidence level, model and adjustments were not directly checked.
Reason for missing information: The MACE+ interval confidence level, model and adjustments were not directly checked.
Required materials and conditions: Estimation model, interval confidence level, adjustments and effect of interest
Materials to obtain first: Estimation model, interval confidence level, adjustments and effect of interest
Further research: If original analysis methods/result tables are supplied, record the definitions of the original HR and interval.
Remaining uncertainty: Do not automatically copy the explicit MACE 95% level to the MACE+ interval or calculate new HRs/CIs. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve original MACE+ HR, interval and P value at each originally stated level.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the MACE+ HR, interval and P value?
Application exceptions: Do not automatically copy the explicit MACE 95% level to the MACE+ interval or calculate new HRs/CIs.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design / M15 §15.3.1–15.3.3; our own application

Related sources R01

N13 · Does null superiority mean zero effect or equivalence?

Current findings: The subclaim note and parent describe the MACE+ superiority result as null. The original HR 0.97 (0.87~1.07), P=.55 is retained without a new zero-effect or equivalence verdict.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Prespecified superiority-analysis details and the clinical-importance threshold are unverified.
Reason for missing information: Prespecified superiority-analysis details and the clinical-importance threshold are unverified.
Required materials and conditions: Prespecified superiority hypothesis, analysis plan and original uncertainty
Materials to obtain first: Prespecified superiority hypothesis, analysis plan and original uncertainty
Further research: If original plans are supplied, distinguish the superiority hypothesis from actual estimates and uncertainty.
Remaining uncertainty: Do not convert nonsignificance to zero event difference, equivalence or a personal safety guarantee. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve the original null-result description together with the uncertainty interval.
Why this condition is needed: A condition for separately recording original information and gaps for: Does null superiority mean zero effect or equivalence?
Application exceptions: Do not convert nonsignificance to zero event difference, equivalence or a personal safety guarantee.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design / M15 §15.3.1–15.3.3; Chamgap adaptation

Related sources R01

N14 · Are the MACE cardiovascular safety results preserved separately?

Current findings: The original summary records the MACE safety endpoint in 364 participants (6.1%) versus 369 (6.2%), HR 0.99 (95% CI 0.85~1.14). It is a different endpoint from MACE+ efficacy superiority.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Detailed MACE components, analysis denominators and model are unverified.
Reason for missing information: Detailed MACE components, analysis denominators and model are unverified.
Required materials and conditions: MACE definitions, denominators, model and original safety estimates
Materials to obtain first: MACE definitions, denominators, model and original safety estimates
Further research: If original safety methods/result tables are supplied, link MACE and MACE+ separately.
Remaining uncertainty: Do not repurpose MACE numbers/CIs as MACE+ efficacy results. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Keep original MACE safety values separate from MACE+ efficacy values.
Why this condition is needed: A condition for separately recording original information and gaps for: Are the MACE cardiovascular safety results preserved separately?
Application exceptions: Do not repurpose MACE numbers/CIs as MACE+ efficacy results.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is our own design

Related sources R01

N15 · To which endpoint does the HR 1.40 noninferiority margin apply?

Current findings: The original summary states that the prespecified HR 1.40 margin for MACE cardiovascular safety noninferiority was met. Original registration/plan text remains unread.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The original planned basis and analysis conditions for the prespecified margin were not directly read.
Reason for missing information: The original planned basis and analysis conditions for the prespecified margin were not directly read.
Required materials and conditions: Planned basis for the noninferiority margin, applicable endpoint and analysis population
Materials to obtain first: Planned basis for the noninferiority margin, applicable endpoint and analysis population
Further research: If original plans are supplied, distinguish the margin’s definition at the time and the reported results.
Remaining uncertainty: Do not use HR 1.40 as a threshold for MACE+ superiority, cancer safety or overall harmlessness. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Link the original margin, applicable MACE endpoint and unread external plans.
Why this condition is needed: A condition for separately recording original information and gaps for: To which endpoint does the HR 1.40 noninferiority margin apply?
Application exceptions: Do not use HR 1.40 as a threshold for MACE+ superiority, cancer safety or overall harmlessness.
Referenced methods: M15 §15.3.1–15.3.3; Chamgap adaptation / M08 Table 8.2.a, M04 §4.6.3; Chamgap adaptation

Related sources R01

N16 · Are the safety/efficacy endpoint hierarchy and testing order known?

Current findings: The original summary explicitly labels MACE as the primary safety endpoint and MACE+ as the primary efficacy endpoint. Hierarchical testing order, alpha allocation and the hierarchy of additional endpoints are absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Actual hierarchy, multiplicity and testing order are unverified.
Reason for missing information: Actual hierarchy, multiplicity and testing order are unverified.
Required materials and conditions: Endpoint hierarchy, testing order, multiplicity and change records
Materials to obtain first: Endpoint hierarchy, testing order, multiplicity and change records
Further research: If the original SAP/registration is supplied, record the prespecified relationship between safety noninferiority and efficacy superiority.
Remaining uncertainty: Do not promote the two primary-endpoint labels to direct certification of all testing procedures. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Distinguish original endpoint roles and unverified hierarchy details.
Why this condition is needed: A condition for separately recording original information and gaps for: Are the safety/efficacy endpoint hierarchy and testing order known?
Application exceptions: Do not promote the two primary-endpoint labels to direct certification of all testing procedures.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap adaptation / M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design

Related sources R01

N17 · Are composite and individual cardiovascular events distinguished?

Current findings: The MACE and MACE+ composite names and original aggregations are preserved. Effects, denominators and CIs for individual components are absent from the summary.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Direct values for death and individual cardiovascular events and overlap among components are unverified.
Reason for missing information: Direct values for death and individual cardiovascular events and overlap among components are unverified.
Required materials and conditions: Definitions, aggregation, HRs/CIs and prespecified hierarchy of individual component events
Materials to obtain first: Definitions, aggregation, HRs/CIs and prespecified hierarchy of individual component events
Further research: If individual-event tables are supplied, separate direct results for the overall composite and each component.
Remaining uncertainty: Do not copy a composite HR as every individual-event HR or mortality benefit. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain the boundary between composite endpoints and unverified individual clinical outcomes.
Why this condition is needed: A condition for separately recording original information and gaps for: Are composite and individual cardiovascular events distinguished?
Application exceptions: Do not copy a composite HR as every individual-event HR or mortality benefit.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design / M03 §3.2.4; our own extension boundary

Related sources R01

N18 · What was the actual cardiovascular analysis observation window?

Current findings: Median follow-up of 3.3 years is preserved context for CAMELLIA overall. Actual MACE/MACE+ event-aggregation windows, follow-up after discontinuation and censoring times are absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Cardiovascular endpoint-specific time definitions and censoring are unverified.
Reason for missing information: Cardiovascular endpoint-specific time definitions and censoring are unverified.
Required materials and conditions: Endpoint-specific start/end times, follow-up after discontinuation and censoring
Materials to obtain first: Endpoint-specific start/end times, follow-up after discontinuation and censoring
Further research: If original follow-up/analysis records are supplied, distinguish median follow-up and actual event windows.
Remaining uncertainty: Do not replace all event windows with the one-year weight time point or median 3.3 years. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Separate original duration descriptions from endpoint-specific timing gaps.
Why this condition is needed: A condition for separately recording original information and gaps for: What was the actual cardiovascular analysis observation window?
Application exceptions: Do not replace all event windows with the one-year weight time point or median 3.3 years.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations by question are our own design / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design

Related sources R01

N19 · What were the HR effect of interest, censoring and competing-risk treatment?

Current findings: Original HRs are supplied, but proportional-hazards assumptions, ITT/actual-use estimands, censoring, competing risks and adjusted models are absent from the summary.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. HR models, effects of interest and competing-risk/censoring handling are unverified.
Reason for missing information: HR models, effects of interest and competing-risk/censoring handling are unverified.
Required materials and conditions: Effect of interest, statistical model, censoring/competing events and sensitivity analyses
Materials to obtain first: Effect of interest, statistical model, censoring/competing events and sensitivity analyses
Further research: If original methods/SAPs are supplied, record the actual estimands and assumptions for each cardiovascular HR.
Remaining uncertainty: Do not interpret an HR as a simple risk ratio or individual prevention probability, or convert it to new values. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Separate original HRs from unverified analysis assumptions.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the HR effect of interest, censoring and competing-risk treatment?
Application exceptions: Do not interpret an HR as a simple risk ratio or individual prevention probability, or convert it to new values.
Referenced methods: M08 §8.2.2, M15 §15.3.1; our own application / M15 §15.3.1–15.3.3; our own application / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations by study design are our own design

Related sources R01

N20 · What is the scope of blinding and cardiovascular event adjudication?

Current findings: The original summary describes CAMELLIA as double-blind and placebo-controlled. Event adjudication committees, data-collection routes and adjudication-blinding details are absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Role-specific blinding, independent adjudication and event-confirmation methods are unverified.
Reason for missing information: Role-specific blinding, independent adjudication and event-confirmation methods are unverified.
Required materials and conditions: Role-specific blinding, event diagnosis/adjudication and unblinding/detection differences
Materials to obtain first: Role-specific blinding, event diagnosis/adjudication and unblinding/detection differences
Further research: If original adjudication/methods material is supplied, record actual roles and event-collection scope.
Remaining uncertainty: Do not extend a double-blind label to certification of every outcome-adjudication or analysis process. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Separate the original design label from gaps in adjudication details.
Why this condition is needed: A condition for separately recording original information and gaps for: What is the scope of blinding and cardiovascular event adjudication?
Application exceptions: Do not extend a double-blind label to certification of every outcome-adjudication or analysis process.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; our own application / M08 §8.1–8.2.3; our own application

Related sources R01

N21 · What are the details of randomization, concealment and baseline balance?

Current findings: The original scale of 12,000 participants randomized 6,000/6,000 is preserved. Sequence generation, concealment, stratification and baseline-balance details are absent from the summary.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Allocation processes, concealment and baseline balance are unverified.
Reason for missing information: Allocation processes, concealment and baseline balance are unverified.
Required materials and conditions: Allocation process, concealment, stratification and baseline-characteristic tables
Materials to obtain first: Allocation process, concealment, stratification and baseline-characteristic tables
Further research: If original allocation/baseline material is supplied, distinguish the design description from actual processes.
Remaining uncertainty: Do not declare all bias conditions satisfied from a randomized label alone. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Keep original allocation labels separate from gaps in direct methods.
Why this condition is needed: A condition for separately recording original information and gaps for: What are the details of randomization, concealment and baseline balance?
Application exceptions: Do not declare all bias conditions satisfied from a randomized label alone.
Referenced methods: M08 §8.1–8.2.3; our own application / M03 §3.2.1; detailed population conditions are our own design

Related sources R01

N22 · How were CAMELLIA attrition, missing data and treatment crossover handled?

Current findings: CAMELLIA allocation size and median follow-up are available, but arm-specific attrition, treatment discontinuation, crossover, missing data and analysis-population details are absent from the summary.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. CAMELLIA endpoint-specific missing-data/attrition and ITT/PP handling details are unverified.
Reason for missing information: CAMELLIA endpoint-specific missing-data/attrition and ITT/PP handling details are unverified.
Required materials and conditions: Arm-specific flow, discontinuation/crossover, missing-data reasons, ITT/PP and sensitivity analyses
Materials to obtain first: Arm-specific flow, discontinuation/crossover, missing-data reasons, ITT/PP and sensitivity analyses
Further research: If original flow/analysis material is supplied, distinguish allocation, use, measurement and analysis denominators.
Remaining uncertainty: Do not transfer BLOOM retention as CAMELLIA follow-up/analysis percentages. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Do not mix denominators and missing-data material across trials.
Why this condition is needed: A condition for separately recording original information and gaps for: How were CAMELLIA attrition, missing data and treatment crossover handled?
Application exceptions: Do not transfer BLOOM retention as CAMELLIA follow-up/analysis percentages.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design / M08 §8.2.2, M15 §15.3.1; our own application / M19 §19.1.2–19.2.4, M04 §4.6.3; our own application

Related sources R01

N23 · Are people, composite events and repeated measurements different units?

Current findings: Original MACE/MACE+ descriptions use people and percentages; cancer diagnoses, primary-cancer counts and weight responses use other outcome units. Events and time points from the same participants are not counted as new participants.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Event overlap, repeated-event handling and exact endpoint-specific at-risk populations are unverified.
Reason for missing information: Event overlap, repeated-event handling and exact endpoint-specific at-risk populations are unverified.
Required materials and conditions: Aggregation rules for people/events/first/repeated events, time points and overlapping outcomes
Materials to obtain first: Aggregation rules for people/events/first/repeated events, time points and overlapping outcomes
Further research: If original aggregation tables are supplied, record each unit and reporting relationship.
Remaining uncertainty: Do not add counts from different endpoints/time points as independent populations or total events. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain original units and do not create unestablished totals.
Why this condition is needed: A condition for separately recording original information and gaps for: Are people, composite events and repeated measurements different units?
Application exceptions: Do not add counts from different endpoints/time points as independent populations or total events.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation

Related sources R01 R05

N24 · Were the NCT and prespecified plans actually compared?

Current findings: The original CAMELLIA trial and FDA reanalysis share NCT02019264. The registration identifier is preserved, but registration, protocol and SAP originals remain unread.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Direct content and timing of preregistration/plans are unverified.
Reason for missing information: Direct content and timing of preregistration/plans are unverified.
Required materials and conditions: Preregistration timing, endpoints/hierarchy, plan changes and analysis documents
Materials to obtain first: Preregistration timing, endpoints/hierarchy, plan changes and analysis documents
Further research: If original registration/plan material is supplied, link actual timing and prespecified definitions.
Remaining uncertainty: Do not count the same NCT as two independent-trial registrations or convert it to certification of prespecification. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Distinguish original registration strings and the scope of unread external material.
Why this condition is needed: A condition for separately recording original information and gaps for: Were the NCT and prespecified plans actually compared?
Application exceptions: Do not count the same NCT as two independent-trial registrations or convert it to certification of prespecification.
Referenced methods: M04 §4.5–4.6 provide collection and selection principles; separating access from reading and the hyperlink convention are our own design / M08 Table 8.2.a, M04 §4.6.3; our own application

Related sources R01 R05

N25 · Are subgroup- and duration-specific cardiovascular effects known?

Current findings: The original summary contains overall MACE/MACE+ values. It lacks effect-modification results by risk, sex, comorbidities, actual exposure amount or duration.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Direct subgroup/duration-specific estimates and interactions are unverified.
Reason for missing information: Direct subgroup/duration-specific estimates and interactions are unverified.
Required materials and conditions: Prespecified subgroup hypotheses, interactions and arm-specific denominators/HRs/intervals
Materials to obtain first: Prespecified subgroup hypotheses, interactions and arm-specific denominators/HRs/intervals
Further research: If subgroup analyses are supplied, separate overall comparisons and subgroup interactions.
Remaining uncertainty: Do not copy the overall HR as an effect for specific populations, durations or optimal exposure. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain gaps in direct evidence outside the overall results.
Why this condition is needed: A condition for separately recording original information and gaps for: Are subgroup- and duration-specific cardiovascular effects known?
Application exceptions: Do not copy the overall HR as an effect for specific populations, durations or optimal exposure.
Referenced methods: M03 §3.2.1; detailed population conditions are our own design / M03 §3.2.1–3.2.4; dose, persistence and effect-modification details are our own design

Related sources R01

N26 · Are superiority’s clinical importance and interpretation of all outcomes the same?

Current findings: The original MACE+ interval and P=.55 are preserved. The superiority result is not extended to guaranteed cardiovascular-event improvement, equivalence or a single conclusion about all benefits/risks.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Prespecified MACE+ clinical-importance criteria and direct absolute effects/intervals are unverified.
Reason for missing information: Prespecified MACE+ clinical-importance criteria and direct absolute effects/intervals are unverified.
Required materials and conditions: Prespecified efficacy-importance criteria, absolute outcomes and individual components/quality of life
Materials to obtain first: Prespecified efficacy-importance criteria, absolute outcomes and individual components/quality of life
Further research: If original importance/outcome material is supplied, record statistical estimates and criteria for clinical scope separately.
Remaining uncertainty: Do not use the MACE noninferiority HR 1.40 as an efficacy-importance threshold. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain the original superiority result’s scope without thresholds from other endpoints.
Why this condition is needed: A condition for separately recording original information and gaps for: Are superiority’s clinical importance and interpretation of all outcomes the same?
Application exceptions: Do not use the MACE noninferiority HR 1.40 as an efficacy-importance threshold.
Referenced methods: M15 §15.3.1–15.3.3; our own application / M03 §3.2.4; our own boundary on extensions

Related sources R01

N27 · Is the CAMELLIA one-year weight response an event effect?

Current findings: CAMELLIA at least 5% weight loss at one year was 38.7% versus 17.4%, P<0.001. The sibling response sheet preserves this response, a different question from the selected cardiovascular event superiority.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Actual endpoint-specific analysis denominators and intervals for weight response are unverified.
Reason for missing information: Actual endpoint-specific analysis denominators and intervals for weight response are unverified.
Required materials and conditions: Boundaries between weight-response definitions, denominators/time points and direct event results
Materials to obtain first: Boundaries between weight-response definitions, denominators/time points and direct event results
Further research: If original results are added, record weight and direct cardiovascular outcomes separately.
Remaining uncertainty: Do not transfer positive weight response as MACE+ superiority or a selected subclaim score. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve sibling context without adding it as new questions or trials.
Why this condition is needed: A condition for separately recording original information and gaps for: Is the CAMELLIA one-year weight response an event effect?
Application exceptions: Do not transfer positive weight response as MACE+ superiority or a selected subclaim score.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design / M03 §3.2.4; Chamgap extension boundary / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design

Related sources R01

N28 · Are BLOOM weight response and retention separate context?

Current findings: BLOOM randomized 3,182 participants; at least 5% loss at 52 weeks was 47.5% versus 20.3%, with one-year retention of 55.4% (883/1595) versus 45.1% (716/1587). This is original weight context.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The original BLOOM registration field is not applicable; actual registration information and cardiovascular superiority material are unverified.
Reason for missing information: The original BLOOM registration field is not applicable; actual registration information and cardiovascular superiority material are unverified.
Required materials and conditions: BLOOM actual analysis denominators, missing data/retention and registration information
Materials to obtain first: BLOOM actual analysis denominators, missing data/retention and registration information
Further research: If original BLOOM material is supplied, link weight results and denominators/retention only to that trial.
Remaining uncertainty: Do not repurpose BLOOM weight/retention values as CAMELLIA events or attrition. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain the boundary between a separate weight trial and selected cardiovascular results.
Why this condition is needed: A condition for separately recording original information and gaps for: Are BLOOM weight response and retention separate context?
Application exceptions: Do not repurpose BLOOM weight/retention values as CAMELLIA events or attrition.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation / M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M03 §3.2.4; Chamgap extension boundary

Related sources R03

N29 · What were the maintenance trial’s 24-week and 52-week results?

Current findings: The maintenance trial concerns 137 participants who lost at least 5% with a low-calorie diet. At 24 weeks, at least 5% maintenance was 73.9% versus 57.4% (P=.033), with additional −2.4±0.8 kg versus +0.6±0.8 kg (P=.010); neither 52-week co-primary result showed a between-group difference.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Quantitative 52-week effects/intervals, each analysis denominator, the meaning of ± and actual registration information are unverified.
Reason for missing information: Quantitative 52-week effects/intervals, each analysis denominator, the meaning of ± and actual registration information are unverified.
Required materials and conditions: Time-specific/co-primary outcome denominators, definitions, intervals, meaning of ± and registration/analysis plans
Materials to obtain first: Time-specific/co-primary outcome denominators, definitions, intervals, meaning of ± and registration/analysis plans
Further research: If original maintenance material is supplied, record time points, co-primary endpoints, denominators and uncertainty.
Remaining uncertainty: Do not transfer a 24-week signal as 52-week weight maintenance or CAMELLIA cardiovascular events. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve original maintenance results and time-specific gaps separately.
Why this condition is needed: A condition for separately recording original information and gaps for: What were the maintenance trial’s 24-week and 52-week results?
Application exceptions: Do not transfer a 24-week signal as 52-week weight maintenance or CAMELLIA cardiovascular events.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap design / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design / M08 Table 8.2.a, M04 §4.6.3; Chamgap adaptation / M03 §3.2.4; Chamgap extension boundary

Related sources R04

N30 · What is the extension scope from weight/maintenance to long-term clinical events?

Current findings: The parent describes weight as a surrogate for clinical events and maintenance results as inconsistent. Cardiovascular superiority is a separate direct MACE+ result.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Long-term clinical benefit and effects after discontinuation that cannot be explained by weight results are unverified.
Reason for missing information: Long-term clinical benefit and effects after discontinuation that cannot be explained by weight results are unverified.
Required materials and conditions: Actual duration-specific clinical outcomes, weight maintenance and follow-up after discontinuation
Materials to obtain first: Actual duration-specific clinical outcomes, weight maintenance and follow-up after discontinuation
Further research: If direct long-term results are supplied, separate trials/time points and surrogates/clinical events.
Remaining uncertainty: Do not automatically extend weight loss to improved long-term events, mortality or quality of life. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve the different outcomes of weight signals and direct cardiovascular events.
Why this condition is needed: A condition for separately recording original information and gaps for: What is the extension scope from weight/maintenance to long-term clinical events?
Application exceptions: Do not automatically extend weight loss to improved long-term events, mortality or quality of life.
Referenced methods: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap design / M03 §3.2.4; Chamgap extension boundary

Related sources R01 R03 R04

N31 · What is the original history of the developer program and independent replication?

Current findings: The original summary states that BLOOM and CAMELLIA share a developer program with overlapping funding and authors, are not independent replication by different research teams/funders, and retain R1.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Current unique-trial counts and exhaustive lists of independent families are not established.
Reason for missing information: Current unique-trial counts and exhaustive lists of independent families are not established.
Required materials and conditions: Original lists of report/developer/author/funding relationships and independent material
Materials to obtain first: Original lists of report/developer/author/funding relationships and independent material
Further research: If relevant material is supplied, distinguish clinical-trial families from funding/author independence.
Remaining uncertainty: Do not calculate independent-replication counts from separate trial/citation counts or regulatory reviews. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve original nonindependent-program history without new independence certification.
Why this condition is needed: A condition for separately recording original information and gaps for: What is the original history of the developer program and independent replication?
Application exceptions: Do not calculate independent-replication counts from separate trial/citation counts or regulatory reviews.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation / Chamgap’s own independence/attribution conditions. The official methodological sections in this pilot do not warrant all these detailed items / M04 §4.6.1–4.6.2, M15 §15.3.1; Chamgap adaptation

Related sources R01 R03

N32 · In which material context do the original FDA cancer-reanalysis results belong?

Current findings: The original summary’s FDA reanalysis of completed data describes 462 people diagnosed with cancer (7.7%, 520 primary cancers) versus 423 (7.1%, 470 cancers), with pancreatic, colorectal and lung cancer imbalances contributing. It concerns safety in the same CAMELLIA trial.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Original regulatory material and cancer-collection/adjudication details remain unread.
Reason for missing information: Original regulatory material and cancer-collection/adjudication details remain unread.
Required materials and conditions: Original FDA communications/review material, cancer definitions, collection/adjudication and event-specific results
Materials to obtain first: Original FDA communications/review material, cancer definitions, collection/adjudication and event-specific results
Further research: If original regulatory material is supplied, record the decision at the time, clinical aggregation and direct content separately.
Remaining uncertainty: Do not turn regulatory reanalysis into a separate efficacy trial, new participants or directly read paper results. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve the original FDA summary as regulatory/safety context.
Why this condition is needed: A condition for separately recording original information and gaps for: In which material context do the original FDA cancer-reanalysis results belong?
Application exceptions: Do not turn regulatory reanalysis into a separate efficacy trial, new participants or directly read paper results.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M19 §19.1.2–19.2.4; detailed discrimination is Chamgap design

Related sources R05

N33 · Are people diagnosed with cancer and primary-cancer counts distinguished?

Current findings: Cancer diagnoses involved 462 versus 423 people, while primary-cancer counts were 520 versus 470: different units. The context is the same 12,000-participant CAMELLIA trial.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Multiple-primary-cancer handling, follow-up/analysis denominators and cancer-type-specific values are unverified.
Reason for missing information: Multiple-primary-cancer handling, follow-up/analysis denominators and cancer-type-specific values are unverified.
Required materials and conditions: People/primary cancers/overlap/duration and at-risk population denominators
Materials to obtain first: People/primary cancers/overlap/duration and at-risk population denominators
Further research: If original cancer-aggregation tables are supplied, link units and observation periods for people and multiple primary cancers.
Remaining uncertainty: Do not add people with cancer and cancer counts or back-calculate duplicate people. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Keep original people, counts and percentages separated and unchanged.
Why this condition is needed: A condition for separately recording original information and gaps for: Are people diagnosed with cancer and primary-cancer counts distinguished?
Application exceptions: Do not add people with cancer and cancer counts or back-calculate duplicate people.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linking is Chamgap adaptation

Related sources R05

N34 · Is one additional cancer per 470 patient-years the original estimate?

Current findings: The original FDA summary of approximately one additional cancer per 470 patient-years of treatment and a widening difference over time is preserved.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Original estimation methods, time-specific tables and cumulative-exposure denominators are unverified.
Reason for missing information: Original estimation methods, time-specific tables and cumulative-exposure denominators are unverified.
Required materials and conditions: Patient-year estimation method, observation windows and time-specific cancer/exposure denominators
Materials to obtain first: Patient-year estimation method, observation windows and time-specific cancer/exposure denominators
Further research: If original time/analysis material is supplied, record the estimate’s observation scope and denominator.
Remaining uncertainty: Do not convert the original 470 patient-years value to individual risk, a new NNH or back-calculated events. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain time/units and estimation limitations in the original regulatory summary.
Why this condition is needed: A condition for separately recording original information and gaps for: Is one additional cancer per 470 patient-years the original estimate?
Application exceptions: Do not convert the original 470 patient-years value to individual risk, a new NNH or back-calculated events.
Referenced methods: M19 §19.2 design-specific harm questions; temporal-relationship details are Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M19 §19.1.2–19.2.4; Chamgap adaptation

Related sources R05

N35 · Are regulatory cancer decisions and statistical confirmation distinguished?

Current findings: The original summary explicitly states that the public FDA safety communication lacked overall-cancer HR, CI and P values, and distinguishes regulatory judgment from statistically confirmed overall-cancer harm.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Direct material on overall-cancer HR, CI, P values and prespecified clinical thresholds remains unread.
Reason for missing information: Direct material on overall-cancer HR, CI, P values and prespecified clinical thresholds remains unread.
Required materials and conditions: Original overall-cancer estimates/intervals, basis for regulatory decisions and prespecified thresholds
Materials to obtain first: Original overall-cancer estimates/intervals, basis for regulatory decisions and prespecified thresholds
Further research: If original statistical/regulatory material is supplied, record original decisions, estimates and uncertainty separately.
Remaining uncertainty: Do not calculate or invent new cancer HRs/CIs/P values, statistical significance or causal certification. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Distinguish original regulatory judgments from gaps in direct statistical material.
Why this condition is needed: A condition for separately recording original information and gaps for: Are regulatory cancer decisions and statistical confirmation distinguished?
Application exceptions: Do not calculate or invent new cancer HRs/CIs/P values, statistical significance or causal certification.
Referenced methods: Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool / M19 §19.1.2–19.2.4; Chamgap adaptation / M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap design

Related sources R05

N36 · What are the original date and scope of the market-withdrawal record?

Current findings: The original summary records the FDA request for voluntary withdrawal on February 13, 2020 and Eisai’s US market withdrawal in 2020. “No longer marketed” is also original wording from the existing reference date.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Current marketing/authorization status was not externally looked up in this production.
Reason for missing information: Current marketing/authorization status was not externally looked up in this production.
Required materials and conditions: Original FDA communication, withdrawal date/region and separate update scope for current product status
Materials to obtain first: Original FDA communication, withdrawal date/region and separate update scope for current product status
Further research: If actual status material is supplied, record withdrawal at the time and verification of current status as separate events.
Remaining uncertainty: Do not promote original historical status to a completed current authorization/marketing lookup. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain original dates and US withdrawal alongside the scope not currently looked up.
Why this condition is needed: A condition for separately recording original information and gaps for: What are the original date and scope of the market-withdrawal record?
Application exceptions: Do not promote original historical status to a completed current authorization/marketing lookup.
Referenced methods: M04 §4.5, §4.6.3; limitations of the current material conversion follow the review scope and Chamgap design / Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool

Related sources R05

N37 · Does cardiovascular noninferiority substitute for cancer or overall safety?

Current findings: The original counterview explicitly states that cardiovascular noninferiority does not substitute for cancer safety. The parent safety warning is preserved as original history.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Details of all harms and other safety endpoints are unverified.
Reason for missing information: Details of all harms and other safety endpoints are unverified.
Required materials and conditions: Endpoint-specific safety results, harm collection and scope of decisions
Materials to obtain first: Endpoint-specific safety results, harm collection and scope of decisions
Further research: If harm material is supplied, record cardiovascular safety, cancer signals and other harms as separate endpoints.
Remaining uncertainty: Do not convert meeting MACE noninferiority to absence of all harms or permission to take the drug. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Separate endpoint-specific safety scope and other long-term harms.
Why this condition is needed: A condition for separately recording original information and gaps for: Does cardiovascular noninferiority substitute for cancer or overall safety?
Application exceptions: Do not convert meeting MACE noninferiority to absence of all harms or permission to take the drug.
Referenced methods: M19 §19.2.2–19.2.4, M03 §3.2.3; Chamgap adaptation / Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool / M19 §19.1.2–19.2.4; Chamgap adaptation

Related sources R01 R05

N38 · Are harm collection, discontinuation and missing follow-up verified?

Current findings: Cancer reanalysis and a safety warning appear in the original summary, but there are no arm-specific tables of systematic/spontaneous harm collection, severity or discontinuation/attrition.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Harm-collection methods, discontinuation/missing data and disclosure scope for all events are unverified.
Reason for missing information: Harm-collection methods, discontinuation/missing data and disclosure scope for all events are unverified.
Required materials and conditions: All-harm collection, event definitions, discontinuation, attrition/missing data and follow-up
Materials to obtain first: All-harm collection, event definitions, discontinuation, attrition/missing data and follow-up
Further research: If original safety flow/tables are supplied, distinguish event collection, unreported results and unread material.
Remaining uncertainty: Do not label a safety summary’s presence as complete collection of all harms or zero events. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Distinguish currently unread material from confirmation that original results were unreported.
Why this condition is needed: A condition for separately recording original information and gaps for: Are harm collection, discontinuation and missing follow-up verified?
Application exceptions: Do not label a safety summary’s presence as complete collection of all harms or zero events.
Referenced methods: M19 §19.1.2–19.2.4; detailed discrimination is Chamgap design / M19 §19.1.2–19.2.4, M04 §4.6.3; Chamgap adaptation / M08 §8.2.2, M15 §15.3.1; Chamgap adaptation

Related sources R01 R05

N39 · What are alternative harm causes and long-term/rare harms or vulnerable populations?

Current findings: The original summary includes cancer imbalance over time, but lacks direct analyses of baseline cancer risk, concurrent treatment and particular populations or rare harms.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct details are absent from the stored summary and remain unverified. External material is unread. Direct material on alternative causes, subgroups, rare harms and other long-term harms is unverified.
Reason for missing information: Direct material on alternative causes, subgroups, rare harms and other long-term harms is unverified.
Required materials and conditions: Baseline/concurrent risks, exposure/follow-up, population-specific harms and alternative explanations
Materials to obtain first: Baseline/concurrent risks, exposure/follow-up, population-specific harms and alternative explanations
Further research: If original long-term/population-specific material is supplied, distinguish original observations from gaps for other populations and rare harms.
Remaining uncertainty: Do not establish a regulatory signal as causality or risk magnitude for all participants, exposures or the class. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Distinguish original signals from unverified alternatives or extension scope.
Why this condition is needed: A condition for separately recording original information and gaps for: What are alternative harm causes and long-term/rare harms or vulnerable populations?
Application exceptions: Do not establish a regulatory signal as causality or risk magnitude for all participants, exposures or the class.
Referenced methods: M19 §19.2.2–19.2.4 design considerations; detailed confounding records are Chamgap design / M19 §19.1.2–19.2.4; Chamgap adaptation / M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap design

Related sources R05

N40 · Are harm records from regulatory reanalysis, a paper and a communication independent replication?

Current findings: The original trial and FDA reanalysis concern the same CAMELLIA population; the related review paper and communication also refer to that trial. They are not added as new independent harm trials.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Independent harm replication and aggregation of new unique events are not established.
Reason for missing information: Independent harm replication and aggregation of new unique events are not established.
Required materials and conditions: Aggregation relationships among original material/re-citations, reviews, communications and papers
Materials to obtain first: Aggregation relationships among original material/re-citations, reviews, communications and papers
Further research: If relevant original documents are supplied, record identity and event relationships between reanalysis and independent material.
Remaining uncertainty: Do not count three documents, the same registration and the same cancer records as three independent populations. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Preserve relationships between document slots and the original population.
Why this condition is needed: A condition for separately recording original information and gaps for: Are harm records from regulatory reanalysis, a paper and a communication independent replication?
Application exceptions: Do not count three documents, the same registration and the same cancer records as three independent populations.
Referenced methods: M04 §4.6.1–4.6.2; harm-material adaptations are Chamgap designs / M04 §4.6.1–4.6.2 on distinguishing studies from reports; cohort and outcome connections are Chamgap adaptations

Related sources R01 R02 R05

N41 · At what level are each report’s funding, author and operational roles recorded?

Current findings: CAMELLIA was fully funded by Eisai, with sponsor co-design/manuscript participation and company-affiliated authors. BLOOM is described as sharing a developer program and overlapping funding/authors. The maintenance-trial funding value is “reported in the original text”.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The maintenance trial’s specific sponsor and complete COI/data access for each report are unverified.
Reason for missing information: The maintenance trial’s specific sponsor and complete COI/data access for each report are unverified.
Required materials and conditions: Original report-specific funding, product provision, analysis/reporting, author affiliations and COI disclosures
Materials to obtain first: Original report-specific funding, product provision, analysis/reporting, author affiliations and COI disclosures
Further research: If original disclosures are supplied, record funding and operational/author roles for each report.
Remaining uncertainty: Do not convert “reported in the original text” to full-text reading in this production or establishment of a specific sponsor. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain original report-specific roles/funding descriptions and gaps separately.
Why this condition is needed: A condition for separately recording original information and gaps for: At what level are each report’s funding, author and operational roles recorded?
Application exceptions: Do not convert “reported in the original text” to full-text reading in this production or establishment of a specific sponsor.
Referenced methods: CHAMGAP's own independence and attribution conditions. Official methodological sections used in this pilot do not guarantee every detail of this item / M04 §4.6.1–4.6.2, M15 §15.3.1; our own application

Related sources R01 R03 R04

N42 · How much of the FDA review paper was actually read?

Current findings: A citation exists for Sharretts et al., PMID 32905671, and its original flag is “no abstract; do not guess content”. The external paper was not read in this production.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. The paper’s own content, direct results and disclosures remain unread.
Reason for missing information: The paper’s own content, direct results and disclosures remain unread.
Required materials and conditions: Paper full text, citation/review context and original conflict-of-interest disclosures
Materials to obtain first: Paper full text, citation/review context and original conflict-of-interest disclosures
Further research: If the user supplies the original full text, record material actually read separately from the FDA communication/summary.
Remaining uncertainty: Do not claim FDA communication values were directly read in the paper because its title mentions the same trial. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain original citation/no-abstract labels and unread status.
Why this condition is needed: A condition for separately recording original information and gaps for: How much of the FDA review paper was actually read?
Application exceptions: Do not claim FDA communication values were directly read in the paper because its title mentions the same trial.
Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and the hyperlink contract are Chamgap design / M04 §4.5, §4.6.3; limitations of the current material conversion follow the review scope and Chamgap design / Chamgap’s own independence/attribution conditions. The official methodological sections in this pilot do not warrant all these detailed items

Related sources R02

N43 · Is extension to other weight-loss drugs or the class avoided?

Current findings: The original advertising discussion explains distinct withdrawal reasons: fenfluramine valvulopathy, sibutramine cardiovascular harms and rimonabant psychiatric harms. These are not direct lorcaserin cardiovascular-superiority material.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Direct event effects and comparative harms of other products/classes are outside this material’s scope.
Reason for missing information: Direct event effects and comparative harms of other products/classes are outside this material’s scope.
Required materials and conditions: Direct product/mechanism/harm-specific material and comparison scope
Materials to obtain first: Direct product/mechanism/harm-specific material and comparison scope
Further research: If material for a separate question is supplied, write each product’s original context separately.
Remaining uncertainty: Do not apply lorcaserin results to other products or the whole class, or create new treatment-selection instructions. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Retain original extension limitations and do not mix results from other products.
Why this condition is needed: A condition for separately recording original information and gaps for: Is extension to other weight-loss drugs or the class avoided?
Application exceptions: Do not apply lorcaserin results to other products or the whole class, or create new treatment-selection instructions.
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap design / M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are Chamgap design / M03 §3.2.4; Chamgap extension boundary / Chamgap’s own interpretation boundary, informed by M19 principles, without running an official causality tool

Related sources R01

N44 · Are the reference date, corrections, Korean/English text and empty-value history preserved?

Current findings: The reference date 2026-08-26, empty corrections array, empty deliberation string, Korean/English text and null/false/empty-string parent-axis values are preserved. Historical marketing/verdict wording is not new current verification.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Partial verification links original stored-summary wording for production; clinical review or verification is not complete. Separate evidence-cutoff/facets keys are absent, and no external latest correction, withdrawal or authorization-status lookup was performed.
Reason for missing information: Separate evidence-cutoff/facets keys are absent, and no external latest correction, withdrawal or authorization-status lookup was performed.
Required materials and conditions: Original dates, corrections, current update scope and original empty values
Materials to obtain first: Original dates, corrections, current update scope and original empty values
Further research: If actual update material is supplied, distinguish the original version and a new correction event.
Remaining uncertainty: Do not borrow the existing reference date as a current review date or convert an empty corrections array to certification that no corrections exist anywhere. Review of the existing content remains incomplete, and external originals were not checked.
Conditions for verification: Link original languages, dates and empty values with the actual current reading scope.
Why this condition is needed: A condition for separately recording original information and gaps for: Are the reference date, corrections, Korean/English text and empty-value history preserved?
Application exceptions: Do not borrow the existing reference date as a current review date or convert an empty corrections array to certification that no corrections exist anywhere.
Referenced methods: M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design / M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are our own design

Related sources R01 R02 R03 R04 R05